

ALIMERA SCIENCES INC

Form DEF 14A

April 29, 2011

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

Alimera Sciences, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

Table of Contents

**Alimera Sciences, Inc.
6120 Windward Parkway
Suite 290
Alpharetta, Georgia 30005**

**NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD JUNE 8, 2011**

To the Stockholders of Alimera Sciences, Inc.:

The annual meeting of stockholders for Alimera Sciences, Inc. (Company) will be held at the Atlanta Marriott Alpharetta, 5750 Windward Parkway, Alpharetta, Georgia 30005, on Wednesday, June 8, 2011 at 9:30 a.m. local time. The purposes of the meeting are:

1. To elect two Class I directors (Proposal 1);
2. To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2011 (Proposal 2);
3. To hold an advisory non-binding vote on executive compensation (Proposal 3);
4. To hold an advisory non-binding vote on the frequency of holding a vote on executive compensation (Proposal 4); and
5. To transact such other business as may properly come before the annual meeting or any adjournments or postponements thereof.

Our board of directors has fixed the close of business on April 13, 2011 as the record date for determining holders of our common stock entitled to notice of, and to vote at, the annual meeting or any adjournments or postponements thereof. A complete list of such stockholders will be available for examination at our offices in Alpharetta, Georgia during normal business hours for a period of ten days prior to the annual meeting.

This notice of annual meeting of stockholders and accompanying proxy statement are being distributed or made available to stockholders on or about April 29, 2011.

Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be held on June 8, 2011: The proxy statement and annual report are available at www.proxyvote.com.

By order of the Board of Directors,

Richard S. Eiswirth, Jr.
Secretary of the Company

Alpharetta, Georgia
Date: April 29, 2011

YOUR VOTE IS IMPORTANT!

Your vote is important. Please vote by using the Internet or by telephone or, if you received a paper copy of the proxy card by mail, by signing and returning the enclosed proxy card. Instructions for your voting options are described on the Notice of Internet Availability of Proxy Materials or proxy card.

ALIMERA SCIENCES, INC.

Proxy Statement
For the Annual Meeting of Stockholders
To Be Held on June 8, 2011

TABLE OF CONTENTS

	Page
<u>QUESTIONS AND ANSWERS</u>	1
<u>PROPOSAL 1: ELECTION OF DIRECTORS</u>	8
<u>Nominees for Election as Class I Directors at the Annual Meeting</u>	8
<u>Required Vote and Recommendation of the Board for Proposal 1</u>	9
<u>Continuing Directors Not Standing for Election</u>	10
<u>CORPORATE GOVERNANCE</u>	12
<u>Independent Directors</u>	12
<u>Board Committees</u>	12
<u>Compensation Committee Interlocks and Insider Participation</u>	14
<u>Board Meetings and Attendance</u>	14
<u>Director Attendance at Annual Meetings of Stockholders</u>	14
<u>Board Leadership</u>	14
<u>Risk Oversight</u>	14
<u>Employee Compensation Risks</u>	15
<u>Code of Business Conduct</u>	15
<u>Limitation of Liability and Indemnification</u>	15
<u>Communications to the Board of Directors</u>	16
<u>Director Compensation</u>	16
<u>Director Compensation Table for Year Ended December 31, 2010</u>	17
<u>PROPOSAL 2: RATIFICATION OF SELECTION OF INDEPENDENT AUDITORS</u>	19
<u>Independent Registered Public Accounting Firm's Fees</u>	19
<u>Pre-Approval Policies and Procedures</u>	20
<u>REPORT OF THE AUDIT COMMITTEE</u>	21
<u>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</u>	22
<u>CERTAIN RELATIONSHIPS AND RELATED PERSONS TRANSACTIONS</u>	26
<u>EXECUTIVE OFFICERS</u>	27
<u>EXECUTIVE COMPENSATION</u>	28
<u>Compensation Discussion and Analysis</u>	28
<u>Policies Regarding Recovery of Awards</u>	40
<u>Tax and Accounting Treatment of Compensation</u>	40
<u>Report of the Compensation Committee</u>	41
<u>2010 Summary Compensation Table</u>	42
<u>Grants of Plan-Based Awards in 2010</u>	43
<u>Outstanding Equity Awards as of December 31, 2010</u>	43
<u>Option Exercises and Stock Vested During 2010</u>	44
<u>Employment Agreements with Our Executive Officers</u>	45
<u>Estimated Benefits and Payments Upon Termination of Employment</u>	46

<u>PROPOSAL 3: ADVISORY NON-BINDING VOTE ON EXECUTIVE COMPENSATION</u>	48
<u>PROPOSAL 4: ADVISORY NON-BINDING VOTE ON THE FREQUENCY OF A VOTE ON EXECUTIVE COMPENSATION</u>	49
<u>NO INCORPORATION BY REFERENCE</u>	50
<u>OTHER MATTERS</u>	50
<u>CONTACT FOR QUESTIONS AND ASSISTANCE WITH VOTING</u>	50

Table of Contents

**ALIMERA SCIENCES, INC.
6120 Windward Parkway
Suite 290
Alpharetta, Georgia 30005
(678) 990-5740**

**PROXY STATEMENT FOR THE
2011 ANNUAL MEETING OF STOCKHOLDERS**

This proxy statement and proxy card are furnished in connection with the solicitation of proxies to be voted at the 2011 Annual Meeting of Stockholders (the Annual Meeting) of Alimera Sciences, Inc. (sometimes referred to as we, the Company or Alimera), which will be held at the Atlanta Marriott Alpharetta, 5750 Windward Parkway, Alpharetta, Georgia 30005, on Wednesday, June 8, 2011 at 9:30 a.m. local time.

We are making this proxy statement and our annual report available to stockholders at www.proxyvote.com. On April 29, 2011, we will begin mailing to our stockholders (i) a copy of this proxy statement, a proxy card and our annual report or (ii) a notice (the Notice) containing instructions on how to access and review this proxy statement and our annual report. The Notice also instructs you how you may submit your proxy over the Internet. If you received a Notice and would like to receive a printed copy of our proxy materials, you should follow the instructions for requesting those materials included in the Notice.

QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING

Why am I receiving this proxy statement and proxy card?

You have received these proxy materials because you owned shares of Alimera common stock as of April 13, 2011, the record date for the Annual Meeting, and our board of directors is soliciting your proxy to vote at the Annual Meeting. This proxy statement describes issues on which we would like you to vote at the Annual Meeting. It also gives you information on these issues so that you can make an informed decision.

Why did I receive a Notice of Internet Availability of Proxy Materials in the mail instead of a printed set of proxy materials?

Pursuant to rules adopted by the Securities and Exchange Commission, we are permitted to furnish our proxy materials over the Internet to our stockholders by delivering a Notice in the mail. As a result, only stockholders that specifically request a printed copy of the proxy statement will receive one. Instead, the Notice instructs stockholders on how to access and review the proxy statement and annual report over the Internet at www.proxyvote.com. The Notice also instructs stockholders on how they may submit their proxy over the Internet. If a stockholder who received a Notice would like to receive a printed copy of our proxy materials, such stockholder should follow the instructions for requesting these materials contained in the Notice.

How may I vote at the Annual Meeting?

You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may simply follow the instructions below to submit your proxy via telephone or on the Internet. If you received or requested a printed set of materials, you may also vote by mail by signing, dating and returning the proxy card.

When you vote by using the Internet or by telephone or by signing and returning the proxy card, you appoint C. Daniel Myers and Richard S. Eiswirth as your representatives (or proxyholders) at the Annual Meeting. They will vote your shares at the Annual Meeting as you have instructed them or, if an issue that is not on the proxy card comes up for vote, in accordance with their best judgment. This way, your shares will be voted whether or not you attend the Annual Meeting.

Table of Contents

Who is entitled to vote at the Annual Meeting?

Only stockholders of record at the close of business on April 13, 2011, the record date for the Annual Meeting, will be entitled to vote at the Annual Meeting. On the record date, there were 31,333,483 shares of the Company's common stock outstanding. All of these outstanding shares are entitled to vote at the Annual Meeting (one vote per share of common stock) in connection with the matters set forth in this proxy statement.

In accordance with Delaware law, a list of stockholders entitled to vote at the meeting will be available at the place of the annual meeting on June 8, 2011 and will be accessible for ten days prior to the meeting at our principal place of business, 6120 Windward Parkway, Suite 290, Alpharetta, Georgia 30005, between the hours of 9:00 a.m. and 5:00 p.m. local time.

How do I vote?

If on April 13, 2011, your shares were registered directly in your name with our transfer agent, American Stock Transfer & Trust Company, then you are a stockholder of record. Stockholders of record may vote by using the Internet, by telephone or (if you received a proxy card by mail) by mail as described below. Stockholders also may attend the meeting and vote in person. If you hold shares through a bank or broker, please refer to your proxy card, Notice or other information forwarded by your bank or broker to see which voting options are available to you.

You may vote by using the Internet. The address of the website for Internet voting is www.proxyvote.com. Internet voting is available 24 hours a day and will be accessible until 11:59 p.m. Eastern Time on June 7, 2011. Easy-to-follow instructions allow you to vote your shares and confirm that your instructions have been properly recorded.

You may vote by telephone. The toll-free telephone number is noted on your proxy card. Telephone voting is available 24 hours a day and will be accessible until 11:59 p.m. Eastern Time on June 7, 2011. Easy-to-follow voice prompts allow you to vote your shares and confirm that your instructions have been properly recorded.

You may vote by mail. If you received a proxy card by mail and choose to vote by mail, simply mark your proxy card, date and sign it, and return it in the postage-paid envelope.

The method you use to vote will not limit your right to vote at the Annual Meeting if you decide to attend in person. Written ballots will be passed out to anyone who wants to vote at the Annual Meeting. If you hold your shares in street name, you must obtain a proxy, executed in your favor, from the holder of record to be able to vote in person at the Annual Meeting.

Can I change my vote after submitting my proxy?

Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of three ways:

You may submit a subsequent proxy by using the Internet, by telephone or by mail with a later date;

You may deliver a written notice that you are revoking your proxy to the Secretary of the Company at 6120 Windward Parkway, Suite 290, Alpharetta, Georgia 30005; or

You may attend the Annual Meeting and vote your shares in person. Simply attending the Annual Meeting without affirmatively voting will not, by itself, revoke your proxy.

If you are a beneficial owner of your shares, you must contact the broker or other nominee holding your shares and follow their instructions for changing your vote.

Table of Contents

How many votes do you need to hold the Annual Meeting?

A quorum of stockholders is necessary to conduct business at the Annual Meeting. Pursuant to our bylaws, a quorum will be present if a majority of the voting power of outstanding shares of the Company entitled to vote generally in the election of directors is represented in person or by proxy at the Annual Meeting. On the record date, there were 31,333,483 shares of common stock outstanding and entitled to vote. Thus, 15,662,742 shares must be represented by stockholders present at the Annual Meeting or represented by proxy to have a quorum.

Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you attend the Annual Meeting and vote in person. Abstentions and broker non-votes will be counted for the purpose of determining whether a quorum is present for the transaction of business. If a quorum is not present, the holders of a majority of the votes present at the Annual Meeting may adjourn the Annual Meeting to another date.

What matters will be voted on at the Annual Meeting?

The following matters are scheduled to be voted on at the Annual Meeting:

Proposal 1: To elect two Class I directors nominated by our board of directors and named in this proxy statement to serve a term of three years until our 2014 annual meeting of stockholders;

Proposal 2: To ratify the selection of Deloitte & Touche LLP as our independent registered public accountants for the year ending December 31, 2011;

Proposal 3: To hold an advisory non-binding vote on executive compensation; and

Proposal 4: To hold an advisory non-binding vote on the frequency of holding a vote on executive compensation.

No cumulative voting rights are authorized, and dissenters' rights are not applicable to these matters.

Could other matters be decided at the Annual Meeting?

Alimera does not know of any other matters that may be presented for action at the Annual Meeting. Should any other business come before the Annual Meeting, the persons named on the proxy card will have discretionary authority to vote the shares represented by proxies in accordance with their best judgment. If you hold shares through a broker, bank or other nominee as described above, they will not be able to vote your shares on any other business that comes before the Annual Meeting unless they receive instructions from you with respect to such other business.

What will happen if I do not vote my shares?

Stockholder of Record: Shares Registered in Your Name. If you are the stockholder of record of your shares and you do not vote by proxy card, by telephone, via the Internet or in person at the Annual Meeting, your shares will not be voted at the Annual Meeting.

Beneficial Owner: Shares Registered in the Name of Broker or Bank. Brokers or other nominees who hold shares of our common stock for a beneficial owner have the discretion to vote on routine proposals when they have not received voting instructions from the beneficial owner at least ten days prior to the Annual Meeting. A broker non-vote occurs when a broker or other nominee does not receive voting instructions from the beneficial owner and does not have the

discretion to direct the voting of the shares. Under the rules that govern brokers who are voting shares held in street name, brokers have the discretion to vote those shares on routine matters but not on non-routine matters. Proposal 2 is the only routine matter in this proxy statement. As such, your broker does not have discretion to vote your shares on Proposals 1, 3 or 4.

We encourage you to provide instructions to your bank or brokerage firm by voting your proxy. This action ensures your shares will be voted at the meeting in accordance with your wishes.

Table of Contents

How may I vote for each proposal and what is the vote required for each proposal?

Proposal 1: Election of two Class I directors.

With respect to the election of nominees for director, you may:

vote **FOR** the election of the two nominees for director;

WITHHOLD your vote for one of the nominees and vote **FOR** the remaining nominee; or

WITHHOLD your vote for the two nominees.

Directors will be elected by a plurality of the votes cast at the Annual Meeting, meaning the two nominees who are properly nominated in accordance with our bylaws, and receive the most **FOR** votes will be elected. Only votes cast **FOR** a nominee will be counted. An instruction to **WITHHOLD** authority to vote for one or more of the nominees will result in those nominees receiving fewer votes, but will not count as a vote against the nominees. Abstentions and broker non-votes will have no effect on the outcome of the election of directors. Because the election of directors is not a matter on which a broker or other nominee is generally empowered to vote, broker non-votes are expected to exist in connection with this matter.

Proposal 2: Ratification of the selection of Deloitte & Touche LLP as our independent registered public accountants for the year ending December 31, 2011.

You may vote **FOR** or **AGAINST** or abstain from voting. To ratify the selection by the audit committee of our board of directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2011, the Company must receive a **FOR** vote from a majority of all those outstanding shares that are present in person, or represented by proxy, and that are cast either affirmatively or negatively on the proposal at the Annual Meeting. Abstentions and broker non-votes will not be counted **FOR** or **AGAINST** the proposal and will have no effect on the proposal. Because the ratification of the appointment of the independent registered public accounting firm is a matter on which a broker or other nominee is generally empowered to vote, no broker non-votes are expected to exist in connection with this matter.

Proposal 3: Advisory non-binding vote on executive compensation.

You may vote **FOR** or **AGAINST** or abstain from voting. To approve, by non-binding vote, the compensation of the Company's named executive officers, the Company must receive a **FOR** vote from a majority of all those outstanding shares that are present in person, or represented by proxy, and that are cast either affirmatively or negatively on the proposal at the Annual Meeting. Abstentions and broker non-votes will not be counted **FOR** or **AGAINST** the proposal and will have no effect on the proposal. Because Proposal 3 is a non-routine matter, broker non-votes are expected to exist in connection with this matter.

Proposal 4: Advisory non-binding vote on the frequency of holding a vote on executive compensation.

You may cast your vote on your preferred voting frequency by choosing the option of **1 year**, **2 years**, **3 years** or abstain from voting. The choice among the three choices which receives the highest number of votes will be deemed the choice of the stockholders. The result of Proposal 4 shall be non-binding on the Company. Abstentions and broker non-votes will not be counted as a vote for any of the three choices and will have no effect on the proposal. Because Proposal 4 is a non-routine matter, broker non-votes are expected to exist in connection with this matter.

What happens if a director nominee is unable to stand for election?

If a nominee is unable to stand for election, our board of directors may either:

reduce the number of directors that serve on the board or

designate a substitute nominee.

Table of Contents

If our board of directors designates a substitute nominee, shares represented by proxies voted for the nominee who is unable to stand for election will be voted for the substitute nominee.

How does our board of directors recommend that I vote?

Our board recommends a vote:

Proposal 1: **FOR** the election of each of C. Daniel Myers and Calvin W. Roberts as Class I directors to serve a term of three years until our 2014 annual meeting of stockholders;

Proposal 2: **FOR** the ratification of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2011;

Proposal 3: **FOR** the approval, in an advisory non-binding manner, of the compensation of our named executive officers; and

Proposal 4: for **1 YEAR**, in an advisory non-binding manner, as your preferred frequency of holding a vote on executive compensation.

What happens if I sign and return my proxy card but do not provide voting instructions?

If you return a signed and dated proxy card without marking any voting selections, your shares will be voted:

Proposal 1: **FOR** the election of each of C. Daniel Myers and Calvin W. Roberts as Class I directors;

Proposal 2: **FOR** the ratification of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2011;

Proposal 3: **FOR** the approval, in an advisory non-binding manner, of the compensation of our named executive officers; and

Proposal 4: for **1 YEAR** as your preferred frequency of holding a vote on executive compensation.

If any other matter is properly presented at the Annual Meeting, the proxyholders for shares voted on the proxy card (i.e. one of the individuals named as proxies on your proxy card) will vote your shares using his or her best judgment.

What do I need to show to attend the Annual Meeting in person?

You will need proof of your share ownership (such as a recent brokerage statement or letter from your broker showing that you owned shares of Alimera Sciences, Inc. common stock as of April 13, 2011) and a form of photo identification. If you do not have proof of ownership and valid photo identification, you may not be admitted to the Annual Meeting. All bags, briefcases and packages will be held at registration and will not be allowed in the meeting. We will not permit the use of cameras (including cell phones with photographic capabilities) and other recording devices in the meeting room.

Who is paying for this proxy solicitation?

The accompanying proxy is being solicited by the board of directors of the Company. In addition to this solicitation, directors and employees of the Company may solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. In addition, the Company may also retain one or more third parties to aid in the solicitation of brokers, banks and institutional and other stockholders. We will pay for the entire cost of soliciting proxies. We may reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.

Table of Contents

What happens if the Annual Meeting is postponed or adjourned?

Unless the polls have closed or you have revoked your proxy, your proxy will still be in effect and may be voted once the Annual Meeting is reconvened. However, you will still be able to change or revoke your proxy with respect to any proposal until the polls have closed for voting on such proposal.

How can I find out the results of the voting at the Annual Meeting?

Preliminary voting results are expected to be announced at the Annual Meeting. Final voting results will be reported on a Current Report on Form 8-K filed with the SEC no later than June 14, 2011.

How can I find Alimera's proxy materials and annual report on the Internet?

This proxy statement and the 2010 annual report are available at our corporate website at www.alimerasciences.com. You also can obtain copies without charge at the SEC's website at www.sec.gov. Additionally, in accordance with SEC rules, you may access these materials at www.proxyvote.com, which does not have cookies that identify visitors to the site.

How do I obtain a separate set of Alimera's proxy materials if I share an address with other stockholders?

In some cases, stockholders holding their shares in a brokerage or bank account who share the same surname and address and have not given contrary instructions received only one copy of the Notice. This practice is designed to reduce duplicate mailings and save printing and postage costs as well as natural resources. If you would like to have a separate copy of the Notice or our annual report and/or proxy statement mailed to you or to receive separate copies of future mailings, please submit your request to the address or phone number that appears on your Notice or proxy card. We will deliver such additional copies promptly upon receipt of such request.

In other cases, stockholders receiving multiple copies of the Notice at the same address may wish to receive only one. If you would like to receive only one copy if you now receive more than one, please submit your request to the address or phone number that appears on your Notice or proxy card.

Can I receive future proxy materials and annual reports electronically?

Yes. This proxy statement and the 2010 annual report are available on our investor relations website located at <http://investor.alimerasciences.com>. Instead of receiving paper copies in the mail, stockholders can elect to receive an email that provides a link to our future annual reports and proxy materials on the Internet. Opting to receive your proxy materials electronically will save us the cost of producing and mailing documents to your home or business, will reduce the environmental impact of our annual meetings and will give you an automatic link to the proxy voting site.

Whom should I call if I have any questions?

If you have any questions, would like additional Alimera proxy materials or proxy cards, or need assistance in voting your shares, please contact Investor Relations, Alimera Sciences, Inc., 6120 Windward Parkway, Suite 290, Alpharetta, Georgia 30005 or by telephone at (310) 954-1105.

Can I submit a proposal for inclusion in the proxy statement for the 2012 annual meeting?

Stockholders of the Company may submit proper proposals for inclusion in our proxy statement and for consideration at our 2012 annual meeting of stockholders by submitting their proposals in writing to the Secretary of the Company in a timely manner. In order to be considered for inclusion in our proxy materials for the 2012 annual meeting of stockholders, stockholder proposals must:

be received by the Secretary of the Company no later than the close of business on December 31, 2011; and

Table of Contents

otherwise comply with the requirements of Delaware law, Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the Exchange Act) and our bylaws.

Unless we receive notice in the foregoing manner, the proxy holders shall have discretionary authority to vote for or against any such proposal presented at our 2012 annual meeting of stockholders. A copy of our bylaw provisions governing the notice requirements set forth above may be obtained by writing to the Secretary of the Company. A current copy of our bylaws also is available at our corporate website at www.alimerasciences.com. Such requests and all notices of proposals and director nominations by stockholders should be sent to Alimera Sciences, Inc., 6120 Windward Parkway, Suite 290, Alpharetta, Georgia 30005, Attention: Secretary of the Company.

**Important Notice Regarding the Availability of Proxy Materials
for the Meeting to be Held on Wednesday, June 8, 2011**

This proxy statement and our annual report are available on-line at www.proxyvote.com.

Table of Contents**MATTERS TO BE CONSIDERED AT THE ANNUAL MEETING****PROPOSAL 1: ELECTION OF DIRECTORS****General**

Our board of directors is currently comprised of eight (8) directors divided into three classes with staggered three-year terms. There are currently two directors in Class I, three directors in Class II and three directors in Class III. The term of office of our Class I directors, C. Daniel Myers and Calvin W. Roberts, M.D. as Class I, will expire at this year's Annual Meeting. The term of office of our Class II directors, Bryce Youngren, Glen Bradley, Ph.D. and Phillip R. Tracy, will expire at the 2012 annual meeting of stockholders. The term of office of our Class III directors, Brian K. Halak, Ph.D., Mark J. Brooks and Peter J. Pizzo, III, will expire at the 2013 annual meeting of stockholders. There are no family relationships among any of our directors or executive officers. It is our policy to encourage nominees for director to attend the Annual Meeting.

Nominees for Election as Class I Directors at the Annual Meeting

This year's nominees for election to the board as our Class I directors to serve for a term of three years expiring at the 2014 annual meeting of stockholders, or until their successors have been duly elected and qualified or until their earlier death, resignation or removal, are provided below. The age of each director as of April 13, 2011 is set forth below. Each of the nominees has agreed to serve as a director if elected, and we have no reason to believe that either nominee will be unable to serve if elected.

Name	Age	Positions and Offices Held with Company	Director Since
C. Daniel Myers	56	Director, President and Chief Executive Officer	2003
Calvin W. Roberts, M.D.	58	Director	2003

The following is additional information about each of the nominees as of the date of this proxy statement, including their business experience, director positions held currently or at any time during the last five years, involvement in certain legal or administrative proceedings, if applicable, and the experiences, qualifications, attributes or skills that caused the nominating/corporate governance committee and our board of directors to determine that the nominees should serve as one of our directors.

C. Daniel Myers is one of our co-founders and has served as our Chief Executive Officer and as a director since the founding of our Company in 2003. Before founding our Company, Mr. Myers was a founding member of Novartis Ophthalmics (formerly CIBA Vision Ophthalmics) and served as its Vice President of Sales and Marketing from 1991 to 1997 and as President from 1997 to 2003. Mr. Myers holds a B.S. in Industrial Management from Georgia Institute of Technology. Our board of directors believes that Mr. Myers should serve as a director of the Company, in light of its business and structure, because in addition to his valuable contributions to our Company in recent years, Mr. Myers has over 27 years of ophthalmic pharmaceutical experience, including 13 years in the role of president and chief executive officer. In addition to serving on our board of directors, Mr. Myers currently holds a directorship with Ocular Therapeutix, Inc.

Calvin W. Roberts, M.D. has been a member of our board of directors since 2003. Dr. Roberts currently serves as the Chief Medical Officer of Bausch + Lomb. Since 1982, Dr. Roberts has served as a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University. Since 1989, Dr. Roberts has also served as a

consultant to Allergan, Inc., Johnson & Johnson and Novartis. Dr. Roberts holds an A.B. from Princeton University and an M.D. from the College of Physicians and Surgeons of Columbia University. Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital in New York and completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston. Our board of directors believes that Dr. Roberts should serve as a director of the Company, in light of its business and structure, because in addition to his valuable contributions to our Company in recent years, Dr. Roberts has an understanding of the market for products in ophthalmology and the nature of the relationship between pharmaceutical companies and physicians derived from his 25 years in

Table of Contents

the practice of medicine as well as his experience in the medical market place and in the processes of drug development and regulatory approval as a consultant to other pharmaceutical companies.

Required Vote and Recommendation of the Board for Proposal 1

The affirmative vote of a plurality of the votes cast at the Annual Meeting is required for the election of our Class I directors. The two nominees receiving the most **FOR** votes among votes properly cast in person or by proxy will be elected to the board as Class I directors. You may vote **FOR** or **WITHHOLD** on each of the nominees for election as director. Shares represented by signed proxy cards will be voted on Proposal 1 **FOR** the election of Mr. Myers and Dr. Roberts to the board of directors at the Annual Meeting, unless otherwise marked on the card. A broker non-vote or a properly executed proxy marked **WITHHOLD** with respect to the election of a Class I director will not be voted with respect to such director, although it will be counted for purposes of determining whether there is a quorum.

**OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU
VOTE FOR C. DANIEL MYERS AND CALVIN W. ROBERTS, M.D.**

Table of Contents**Continuing Directors Not Standing for Election**

Certain information about those directors whose terms do not expire at the Annual Meeting is furnished below, including their business experience, director positions held currently or at any time during the last five years, involvement in certain legal or administrative proceedings, if applicable, and the experiences, qualifications, attributes or skills that caused the nominating/corporate governance committee and our board of directors to determine that the directors should serve as one of our directors. The age of each director as of April 13, 2011 is set forth below.

Name	Age	Positions and Offices Held with Company	Director Since
Philip R. Tracy	69	Chairman of the Board of Directors	2004
Mark J. Brooks	44	Director	2004
Brian K. Halak, Ph.D.	39	Director	2004
Bryce Youngren	40	Director	2005
Peter J. Pizzo, III	44	Director	2010
Glen Bradley, Ph.D.(1)	68	Director	2011

(1) Appointed to the board of directors effective as of April 18, 2011.

Class II Directors (Terms Expire in 2012)

Philip R. Tracy has been a member of our board of directors since 2004. Since 1998, Mr. Tracy has served as a Venture Partner of Intersouth Partners. He is also counsel to the Raleigh, North Carolina law firm Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. Previously, Mr. Tracy was employed by Burroughs Wellcome Co. from 1974 to 1995 and served as President and Chief Executive Officer from 1989 to 1995. Mr. Tracy holds an L.L.B. from George Washington University and a B.A. from the University of Nebraska. Our board of directors believes that Mr. Tracy should serve as a director of the Company, in light of its business and structure, because in addition to his valuable contributions to our Company in recent years, Mr. Tracy has served on the board of directors of three publicly traded companies in the biotechnology and pharmaceutical industries, has experience as president and chief executive officer of Burroughs Wellcome Co. with full responsibility for its North American pharmaceutical business, has legal training and experience as a lawyer including his service as general counsel to Burroughs Wellcome Co., and has 10 years of experience in the venture capital industry as a venture partner with Intersouth Partners.

Bryce Youngren has been a member of our board of directors since 2005. Since 2002, Mr. Youngren has worked at Polaris Venture Partners, most recently as a General Partner. Prior to joining Polaris, Mr. Youngren served as a Senior Associate at Great Hill Partners from 1999 to 2002. From 1996 to 1997, Mr. Youngren served as an Analyst for Willis Stein & Partners. From 1994 to 1996, Mr. Youngren served as an Analyst for Bear Stearns & Co. Mr. Youngren holds an M.B.A. from The Wharton School at the University of Pennsylvania and a B.A. in Economics from the University of Illinois at Urbana-Champaign. Our board of directors believes that Mr. Youngren should serve as a director of the Company, in light of its business and structure, because in addition to his valuable contributions to our Company in recent years, Mr. Youngren has experience in the venture capital industry since 1996 and has served on the board of directors of nine companies (including our Company).

Glen Bradley, Ph.D., M.B.A., has been a member of our board of directors since 2011. Dr Bradley served as the Chief Executive Officer of CIBA Vision Corporation, the eye care unit of Novartis, A.G., or CIBA Vision, from 1990 to

January 2003. Since 2003, Dr Bradley has acted as a consultant to various medical device and ophthalmic drug companies. Dr. Bradley served in the positions of President and CEO from 1986 to 1989 for CIBA Vision, the United States operations of the CIBA Vision Group. Prior to CIBA Vision, he served in senior management positions in the Agricultural, Plastics & Additives and Electronic Equipment Groups of CIBA-Geigy Corporation. Dr. Bradley has been Chairman of the Board of Directors at REFOCUS Group Inc., since March 2003. He serves as a Director of Intuity Medical, Inc. He has previously held board positions with Spectra Physics, Summit Technology, Biofisica, AerovectRx, e-Dr and Biocure. He served as Chairman of the Contact Lens Institute. Dr. Bradley holds a bachelor s degree in chemical engineering from

Table of Contents

Mississippi State University, a Ph.D. in chemical engineering from Louisiana State University, an MBA in business and finance from the University of Connecticut and is a graduate of the Advanced Management Program at Harvard Business School. Our board of directors believes that Dr. Bradley should serve as a director of the Company, in light of its business and structure, because of his significant knowledge, experience, and financial expertise in the ophthalmic industry.

Class III Directors (Terms Expire in 2013)

Mark J. Brooks has been a member of our board of directors since 2004. Since its formation in January 2007, Mr. Brooks has served as a Managing Director of Scale Venture Partners. Prior to joining Scale Venture Partners, from 1995 Mr. Brooks worked for Bank of America Ventures, ultimately serving as a Managing Director. Mr. Brooks also serves on the Board of Directors of IPC The Hospitalist Company, Inc., a publicly traded provider of hospitalist services, and also serves on the Board of four privately held companies: National Healing Corporation, LivHome, Inc., Spinal Kinetics, Inc., and Oraya Therapeutics, Inc. Mr. Brooks holds an M.B.A. from the Wharton School at the University of Pennsylvania and a B.A. in Economics from Dartmouth College. Our board of directors believes that Mr. Brooks should serve as a director of the Company, in light of its business and structure, because in addition to his valuable contributions to our Company in recent years, Mr. Brooks has experience as one of six managing directors of Scale Venture Partners, where Mr. Brooks leads investments in healthcare services, medical devices and drug development and his service on the board of directors of a number of Scale Venture Partners portfolio companies.

Brian K. Halak, Ph.D. has been a member of our board of directors since 2004. Since 2006, Dr. Halak has served as a Partner of Domain Associates, L.L.C. Prior to joining Domain Associates, L.L.C., Dr. Halak served as an analyst of Advanced Technology Ventures from 2000 to 2001. From 1993 to 1995, Dr. Halak has served as an analyst of Wilkerson Group. Dr. Halak holds a Doctorate in Immunology from Thomas Jefferson University and a B.S. in Engineering from the University of Pennsylvania. Our board of directors believes that Dr. Halak should serve as a director of the Company, in light of its business and structure, because in addition to his valuable contributions to our Company in recent years, Dr. Halak has served on the board of directors of 10 emerging companies in the life sciences industry in the past 10 years, including Vanda Pharmaceuticals, which completed a public offering on NASDAQ, and Espirit Pharma, a company that was acquired by Allergan.

Peter J. Pizzo, III has been a member of our board of directors since April 2010. Since its formation in 2005, Mr. Pizzo has served as the Vice President, Finance and Chief Financial Officer of Carticept Medical, Inc., a private orthopedic medical device company, which he co-founded. From 2002 until its sale in 2005, Mr. Pizzo served as the Vice President, Finance and Chief Financial Officer of Proxima Therapeutics, Inc., a private medical device company that developed and marketed local radiation delivery systems for the treatment of solid cancerous tumors. From 1996 to 2001, Mr. Pizzo worked for Serologicals Corporation, a publicly traded global provider of biological products to life science companies, ultimately serving as Vice President of Finance and Chief Financial Officer. From 1995 to 1996, Mr. Pizzo served as Vice President of Administration and Controller of ValueMark Healthcare Systems, Inc., a privately held owner-operator of psychiatric hospitals. From 1992 until its sale in 1995, Mr. Pizzo served in various senior financial positions at Hallmark Healthcare Corporation, a publicly traded hospital management company, most recently as Treasurer. Mr. Pizzo holds a Bachelor of Science with Special Attainments in Commerce from Washington and Lee University. Our board of directors believes that Mr. Pizzo should serve as a director of the Company, in light of its business and structure, because Mr. Pizzo has over 18 years of experience in medical devices, biologics and healthcare services, including the past ten years in the role of vice president, finance and chief financial officer.

Table of Contents**CORPORATE GOVERNANCE****Independent Directors**

Each of our directors other than C. Daniel Myers qualifies as an independent director in accordance with the published listing requirements of the Nasdaq Global Market, or Nasdaq. The Nasdaq independence definition includes a series of objective tests, such as that the director is not also one of our employees and has not engaged in various types of business dealings with us. In addition, as further required by the Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our directors reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities as they may relate to us and our management.

Board Committees

Our board of directors has established an audit committee, a compensation committee and a nominating/corporate governance committee. Our board of directors and its committees set schedules to meet throughout the year, and also can hold special meetings and act by written consent from time to time as appropriate. The independent directors of our board of directors also will hold separate regularly scheduled executive session meetings at least twice a year at which only independent directors are present. Our board of directors has delegated various responsibilities and authority to its committees as generally described below. The committees will regularly report on their activities and actions to the full board of directors. Each current member of each committee of our board of directors qualifies as an independent director in accordance with the Nasdaq standards described above and SEC rules and regulations. Each committee of our board of directors has a written charter approved by our board of directors. Copies of each charter will be posted on our website at <http://www.alimerasciences.com> under the Investor Relations section. The inclusion of our website address in this proxy statement does not include or incorporate by reference the information on our website into this proxy statement.

The following table provides membership and meeting information for each of the committees of the board of directors during 2010:

Committee	Chairman	Members	Number of Meetings in 2010
Audit Committee	Peter J. Pizzo, III(1)	Glen Bradley, Ph.D.(2) Mark J. Brooks (3) Anders D. Hove, M.D. (4) Calvin W. Roberts, M.D.	3
Compensation Committee		Mark J. Brooks Anders D. Hove, M.D. (4)	
Nominating/Corporate Governance Committee	Brian K. Halak, Ph.D.	Bryce Youngren (5) Brian K. Halak, Ph.D. Bryce Youngren	5
	Philip R. Tracy	Youngren	0

- (1) Replaced Mr. Brooks as a member of the audit committee in April 2010.
- (2) Appointed as a member of the audit committee in April 2011.
- (3) Resigned as a member of the audit committee in April 2010.
- (4) Resigned as a director and member of the audit committee and compensation committee in April 2011.
- (5) Replaced Dr. Hove as a member of the compensation committee in April 2011.

Table of Contents

The primary responsibilities of each committee are described below.

Audit Committee

Our audit committee currently consists of Peter J. Pizzo, III, Calvin W. Roberts, M.D. and Glen Bradley, Ph.D. Mr. Pizzo serves as the chairman of the audit committee. Following the resignation of Anders D. Hove, M.D. as a member of the board of directors and audit committee effective April 18, 2011, Dr. Bradley was appointed as a member of the audit committee. Our board of directors annually reviews the Nasdaq listing standards definition of independence for audit committee members and has determined that all current members of our audit committee are independent (as independence is currently defined in applicable Nasdaq listing standards and Rule 10A-3 promulgated under the Exchange Act).

Mr. Pizzo qualifies as an audit committee financial expert as that term is defined in the rules and regulations of the SEC. The designation of Mr. Pizzo as an audit committee financial expert does not impose on him any duties, obligations or liability that are greater than those that are generally imposed on him as a member of our audit committee and our board of directors, and his designation as an audit committee financial expert pursuant to this SEC requirement does not affect the duties, obligations or liability of any other member of our audit committee or board of directors.

The audit committee monitors our corporate financial statements and reporting and our external audits, including, among other things, our internal controls and audit functions, the results and scope of the annual audit and other services provided by our independent registered public accounting firm and our compliance with legal matters that have a significant impact on our financial statements. Our audit committee also consults with our management and our independent registered public accounting firm prior to the presentation of financial statements to stockholders and, as appropriate, initiates inquiries into aspects of our financial affairs. Our audit committee is responsible for establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters and for the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters. Our audit committee monitors compliance with our Code of Business Conduct policy. In addition, our audit committee is directly responsible for the appointment, retention, compensation and oversight of the work of our independent auditors, including approving services and fee arrangements. Related party transactions will be approved by our audit committee before we enter into them, in accordance with the applicable rules of Nasdaq.

Both our independent registered public accounting firm and internal financial personnel regularly meet with, and have unrestricted access to, the audit committee.

Compensation Committee

Our compensation committee consists of Mark J. Brooks, Brian K. Halak, Ph.D. and Bryce Youngren. Dr. Halak serves as chairman of the compensation committee. Anders D. Hove, M.D. resigned as a member of our board of directors and compensation committee effective as of April 18, 2011. Our board of directors has determined that Mr. Brooks, Dr. Halak and Mr. Youngren satisfy the independence requirements of the Nasdaq and the SEC rules and regulations for directors. Each member of this committee is a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the Securities Exchange Act of 1934, as amended, and an outside director, as defined pursuant to Section 162(m) of the Internal Revenue Code of 1986, as amended.

The compensation committee makes recommendations to the board of directors and reviews and approves our compensation policies and all forms of compensation to be provided to our directors and executive officers, including,

among other things, annual salaries, bonuses, and stock option and other incentive compensation arrangements. In addition, our compensation committee will administer our stock option and employee stock purchase plans, including granting stock options to our directors and executive officers. Our compensation committee also reviews and approves employment agreements with executive officers and other compensation policies and matters.

Table of Contents

Nominating/Corporate Governance Committee

Our nominating/corporate governance committee currently consists of Brian K. Halak, Philip R. Tracy and Bryce Youngren. Mr. Tracy serves as chairman of the nominating/corporate governance committee. Our board of directors has determined that Dr. Halak, Messrs. Tracy and Youngren satisfy the independence requirements of the Nasdaq and the SEC rules and regulations for directors.

Our nominating/corporate governance committee identifies, evaluates and recommends nominees to our board of directors and committees of our board of directors, conducts searches for appropriate directors and evaluates the performance of our board of directors and of individual directors. In evaluating potential nominees to the board of directors, the nominating/corporate governance committee considers a wide variety of qualifications, attributes and other factors and recognizes that a diversity of viewpoints and practical experience can enhance the effectiveness of our board of directors. Accordingly, as part of its evaluation of each candidate, the nominating/corporate governance committee takes into account that candidate's background, experience, qualifications, attributes and skills that may complement, supplement or duplicate those of other prospective candidates and current directors. The nominating/corporate governance committee is also responsible for reviewing developments in corporate governance practices, evaluating the adequacy of our corporate governance practices and reporting and making recommendations to the board concerning corporate governance matters. Our nominating/corporate governance committee has not adopted a policy regarding the consideration of diversity in identifying director nominees.

Compensation Committee Interlocks and Insider Participation

As noted above, the compensation committee of our board of directors currently consists of Mark J. Brooks, Brian K. Halak and Bryce Youngren. None of our executive officers serves as a member of the board of directors or compensation committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or compensation committee. None of the current members of our compensation committee has ever been employed by us.

Board Meetings and Attendance

Our board of directors held seven (7) meetings in 2010. In 2010, each member of the board attended 75% or more of the aggregate of (i) the total number of board meetings held during the period of such member's service and (ii) the total number of meetings of committees on which such member served, during the period of such member's service.

Director Attendance at Annual Meetings of Stockholders

Directors are encouraged, but not required, to attend our annual stockholder meetings. This annual meeting will be our first as a public company.

Board Leadership

Our board of directors is led by our chairman of the board. The chairman of the board chairs all board meetings (including executive sessions), approves board agendas and schedules, and oversees board materials. The chairman of the board also acts as liaison between the independent directors and management, approves board meeting schedules and oversees the information distributed in advance of board meetings, is available to our outside corporate counsel to discuss and, as necessary, respond to stockholder communications to our board of directors, and calls meetings of the independent directors. We believe that having different people serving in the roles of chairman of the board and chief executive officer is an appropriate and effective organizational structure for our Company.

Risk Oversight

Our board of directors oversees the management of risks inherent in the operation of our business and the implementation of our business strategies. Our board of directors performs this oversight role by using several

Table of Contents

different levels of review. In connection with its reviews of the operations and corporate functions of our Company, our board of directors addresses the primary risks associated with those operations and corporate functions. In addition, our board of directors reviews the risks associated with our Company's business strategies periodically throughout the year as part of its consideration of undertaking any such business strategies.

Each of our board committees also oversees the management of our Company's risk that falls within the committee's areas of responsibility. In performing this function, each committee has full access to management, as well as the ability to engage advisors. Our Chief Financial Officer reports to the audit committee with respect to risk management and is responsible for identifying, evaluating and implementing risk management controls and methodologies to address any identified risks. In connection with its risk management role, our audit committee meets privately with representatives from our independent registered public accounting firm and our Chief Financial Officer. The audit committee oversees the operation of our risk management program, including the identification of the primary risks associated with our business and periodic updates to such risks, and reports to our board of directors regarding these activities.

Employee Compensation Risks

As part of its oversight of our Company's executive compensation program, the compensation committee considers the impact of the program, and the incentives created by the compensation awards that it administers, on our Company's risk profile. In addition, the compensation committee reviews all of our Company's compensation policies and procedures, including the incentives that they create and factors that may reduce the likelihood of excessive risk taking, to determine whether they present a significant risk to our Company. The compensation committee has determined that, for all employees, our Company's compensation programs are not reasonably likely to have a material adverse effect on the Company.

Code of Business Conduct

Our board of directors has adopted a code of ethics and business conduct that applies to all of our employees, executive officers (including our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions) and directors. The full text of our code of ethics and business conduct will be posted on our website at www.alimerasciences.com under the Investor Relations section. We intend to disclose future amendments to certain provisions of our code of ethics and business conduct, or waivers of such provisions, applicable to our directors and executive officers at the same location on our website identified above and also in a Current Report on Form 8-K, as required, within four business days following the date of such amendment or waiver. The inclusion of our website address in this proxy statement does not include or incorporate by reference the information on our website into this proxy statement.

Limitation of Liability and Indemnification

We have entered into indemnification agreements with each of our directors and executive officers. The agreements provide that we will indemnify each of our directors and executive officers against any and all expenses incurred by that director or executive officer because of his or her status as one of our directors or executive officers, to the fullest extent permitted by Delaware law, our restated certificate of incorporation and bylaws. In addition, the agreements provide that, to the fullest extent permitted by Delaware law, but subject to various exceptions, we will advance all expenses incurred by our directors in connection with a legal proceeding.

Our restated certificate of incorporation and bylaws contain provisions relating to the limitation of liability and indemnification of directors. The restated certificate of incorporation provides that our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for

liability:

for any breach of the director's duty of loyalty to us or our stockholders;

Table of Contents

for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

in respect of unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or

for any transaction from which the director derives any improper personal benefit.

Our restated certificate of incorporation also provides that if Delaware law is amended, after the approval by our stockholders of our restated certificate of incorporation, to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law. The foregoing provisions of the restated certificate of incorporation are not intended to limit the liability of directors or officers for any violation of applicable federal securities laws. As permitted by Section 145 of the Delaware General Corporation Law, our restated certificate of incorporation provides that we may indemnify our directors to the fullest extent permitted by Delaware law and the restated certificate of incorporation provisions relating to indemnity may not be retroactively repealed or modified so as to adversely affect the protection of our directors.

In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws provide that we are authorized to enter into indemnification agreements with our directors and executive officers and we are authorized to purchase directors and officers liability insurance, which we currently maintain to cover our directors and executive officers

Communications to the Board of Directors

Stockholders interested in communicating with the independent directors regarding their concerns or issues may address correspondence to a particular director, or to the independent directors generally, in care of Alimera Sciences, Inc. 6120 Windward Parkway, Suite 290, Alpharetta, Georgia 30005, Attn: Secretary of the Company. The Secretary of the Company has the authority to disregard any inappropriate communications or to take other appropriate actions with respect to any inappropriate communications. If deemed an appropriate communication, the Secretary of the Company will forward it, depending on the subject matter, to the chairman of the board of directors, chairman of a committee of the board of directors, the full board of directors or a particular director, as appropriate.

Director Compensation

On October 27, 2009, our board of directors adopted a compensation program for outside directors, which became effective upon the consummation of our initial public offering in April 2010. Pursuant to this program, each member of our board of directors who is not our employee will receive a \$20,000 annual cash retainer, other than the chairman of our board of directors who will receive a \$25,000 annual cash retainer. The chairman of the audit committee will receive an additional annual retainer of \$7,500, and the chairman of each other committee will receive an additional annual retainer of \$3,500. Each other non-employee director serving as a member of a committee will receive an additional annual retainer of \$2,000 for service on that committee. All retainer fees will be paid in four quarterly payments. Our compensation committee has recently engaged Hewitt Associates to review our director compensation program.

Each non-employee director who served as a board member prior to the effective date of the registration statement for our initial public offering and who continued to serve as a member of the board of directors after such date received a one-time option award to purchase 7,500 shares of our common stock, which vests and becomes exercisable with respect to 25% of the option shares after one year of service on the board of directors and an additional 6.25% of the

option shares for each subsequent three-month period thereafter.

Each non-employee director who first becomes a member of the board of directors after our initial public offering will receive an initial, one-time option award to purchase 20,000 shares of our common stock upon his or her election to our board of directors, which vests and becomes exercisable with respect to 25% of the option shares after one year of service on the board of directors and an additional 6.25% of the option shares for each subsequent three-month period thereafter.

Table of Contents

Each year beginning in 2011, each non-employee director who will continue to be a director after the annual meeting of our stockholders will be granted an option for 7,500 shares of our common stock at that annual meeting, which will be vested and exercisable in full on the date of grant. However, a non-employee director who receives an option to purchase 20,000 shares in connection with joining the board of directors will not also receive the annual option to purchase 7,500 shares in the same calendar year.

Each option granted under the directors' option grant program that is not fully vested on the date of grant will become fully vested upon a change in control of our Company and will also become fully vested if the non-employee director's service terminates due to death. All options granted to the non-employee directors will have an exercise price equal to the fair market value of our common stock on the date of the grant.

We currently have a policy to reimburse our non-employee directors for travel, lodging and other reasonable expenses incurred in connection with their attendance at board and committee meetings.

Director Compensation Table for Year Ended December 31, 2010

The following table sets forth information regarding compensation earned by each of our non-employee directors during the fiscal year ended December 31, 2010 (this table excludes Glen Bradley, Ph.D., who was appointed to the board of directors effective as of April 18, 2011):

Name(1)	Fees Earned or Paid in Cash (\$)	Option Awards (\$)(2)	Total (\$)
Mark J. Brooks	\$ 15,231	\$ 67,835	\$ 83,066
Brian K. Halak, Ph.D.	17,654	67,835	85,489
Anders D. Hove, M.D.(3)	16,615	67,835	84,450
Peter J. Pizzo, III(4)	19,038	180,894	199,932
Calvin W. Roberts, M.D.	18,923	67,835	86,758
Philip R. Tracy	19,731	67,835	87,566
Bryce Youngren	15,231	67,835	83,066

(1) Mr. Myers was not eligible in 2010 to receive any compensation from us for service as a director pursuant to our director compensation plan because Mr. Myers is a Company employee.

(2) The amounts reported in this column represent the aggregate grant date fair value of option awards computed in accordance with FASB ASC Topic 718. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. See Note 12 of the Notes to the Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2010 for a discussion of our assumptions in determining the ASC 718 values of our option awards.

(3) Dr. Hove resigned as a member of the board of directors effective April 18, 2011.

(4) Mr. Pizzo was appointed to the board of directors effective April 22, 2010.

Table of Contents

The following table sets forth information regarding outstanding option awards held by each of our non-employee directors as of December 31, 2010 (this table excludes Glen Bradley, Ph.D., who was appointed to the board of directors effective as of April 18, 2011):

Name	Option awards			
	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Option Exercise Price (\$)	Option Expiration Date
Mark J. Brooks		7,500	11.00	April 27, 2020(2)
Brian K. Halak, Ph.D.		7,500	11.00	April 27, 2020(2)
Anders D. Hove, M.D.		7,500	11.00	April 27, 2020(2)
Peter J. Pizzo, III(1)		20,000	11.00	April 27, 2020(2)
Calvin W. Roberts, M.D.	4,412		2.04	December 31, 2011(3)
	4,412		2.04	July 1, 2012(3)
	8,824		1.33	December 14, 2013(3)
	4,412		3.88	June 25, 2015(3)
	4,412		4.02	June 16, 2016(3)
		7,500	11.00	April 27, 2020(2)
Philip R. Tracy		7,500	11.00	April 27, 2020(2)
Bryce Youngren		7,500	11.00	April 27, 2020(2)

- (1) Mr. Pizzo was appointed to the board of directors effective April 22, 2010.
- (2) Exercisable with respect to 25% of the shares of stock which are subject to this option on April 27, 2011 (the Initial Vesting Date), provided the optionee provides continuous service to Alimera through the Initial Vesting Date; and the remainder of the shares of stock which are subject to this option shall vest in equal increments quarterly over three years beginning on the date three months from such Initial Vesting Date, provided optionee provides continuous service to Alimera through the last day of each quarterly period.
- (3) Exercisable with respect to 100% of the shares of stock which are subject to this option as of the date of grant.

Table of Contents**PROPOSAL 2****RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

The audit committee of our board of directors has selected Deloitte & Touche LLP, an independent registered public accounting firm, as our independent auditors for the year ending December 31, 2011, and has further directed that management submit the selection of independent auditors for ratification by the stockholders at the Annual Meeting. Deloitte & Touche LLP has audited our financial statements since the year ended December 31, 2005. Representatives of Deloitte & Touche LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

Neither our bylaws nor other governing documents or laws require stockholder ratification of the selection of Deloitte & Touche LLP as our independent registered public accounting firm. However, the audit committee of the board of directors is submitting the selection of Deloitte & Touche LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the audit committee of the board of directors will reconsider whether or not to retain Deloitte & Touche LLP. Even if the selection is ratified, the audit committee of our board of directors in its discretion may direct the appointment of different independent auditors at any time during the year if it determines that such a change would be in the best interests of the Company and our stockholders.

In order for Proposal 2 to pass, holders of a majority of all those outstanding shares present in person, or represented by proxy, and cast either affirmatively or negatively at the Annual Meeting must vote **FOR** Proposal 2. Abstentions and broker non-votes will be counted towards a quorum, however, they will not be counted either **FOR** or **AGAINST** the proposal and will have no effect on the proposal. Because the ratification of the appointment of the independent registered public accounting firm is a matter on which a broker or other nominee is generally empowered to vote, no broker non-votes are expected to exist in connection with this matter.

Independent Registered Public Accounting Firm's Fees

The following table represents aggregate fees billed to the Company for the years ended December 31, 2010, and December 31, 2009, by Deloitte & Touche LLP, our principal accountant.

	Year Ended December 31,	
	2010	2009
Audit fees(1)	\$ 445,400	\$ 354,200
Audit-related fees		
Tax fees(2)	45,000	
All other fees	5,000	5,300
Total fees	\$ 495,400	\$ 359,500

(1) The fees billed or incurred by Deloitte & Touche LLP for professional services rendered in connection with the annual audit of our consolidated financial statements for the year ending December 31, 2010 include the review

of quarterly financial statements included in our quarterly reports on Form 10-Q and the review and consent issued for our registration statements on Form S-1 and Form S-8.

- (2) Fees billed or incurred by Deloitte & Touche LLP for professional services rendered in connection with the Company's application for Qualifying Therapeutic Discovery Project tax credits available under Internal Revenue Code 48D.

All fees described above were pre-approved by the audit committee in accordance with the requirements of Regulation S-X under the Exchange Act.

Table of Contents

Pre-Approval Policies and Procedures

The audit committee's policy is to pre-approve all audit and permissible non-audit services rendered by Deloitte & Touche LLP, our independent registered public accounting firm. The audit committee can pre-approve specified services in defined categories of audit services, audit-related services and tax services up to specified amounts, as part of the audit committee's approval of the scope of the engagement of Deloitte & Touche LLP or on an individual case-by-case basis before Deloitte & Touche LLP is engaged to provide a service. The audit committee has determined that the rendering of tax-related services by Deloitte & Touche LLP is compatible with maintaining the principal accountant's independence for audit purposes. Deloitte & Touche LLP has not been engaged to perform any non-audit services other than tax-related services.

YOUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS YOU VOTE THE PROXY CARD FOR PROPOSAL 2

Table of Contents

REPORT OF THE AUDIT COMMITTEE¹

The audit committee of our board of directors operates pursuant to a charter which is reviewed annually by the audit committee. Additionally, a brief description of the primary responsibilities of the audit committee is included in this proxy statement under Corporate Governance Board Committees Audit Committee . Under the audit committee charter, our management is responsible for the preparation, presentation and integrity of our financial statements, the application of accounting and financial reporting principles and our internal controls and procedures designed to assure compliance with accounting standards and applicable laws and regulations. The independent registered public accounting firm is responsible for auditing our financial statements and expressing an opinion as to their conformity with accounting principles generally accepted in the United States of America.

In the performance of its oversight function, the audit committee reviewed and discussed the audited financial statements of the Company with management and with the independent registered public accounting firm. The audit committee also discussed with the independent registered public accounting firm the matters required to be discussed by Statement of Accounting Standards 61 as amended (Codification of Statements on Auditing Standards AU 380) and as adopted by the Public Company Accounting Oversight Board (PCAOB), in Rule 3200T, including the quality, not just the acceptability of the accounting principles, the reasonableness of significant estimates, and the clarity of the disclosures in the financial statements. In addition, the audit committee received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent registered public accounting firm s communications with the audit committee concerning independence, and discussed with the independent registered public accounting firm their independence.

The audit committee has adopted a charter and a process for pre-approving services to be provided by the independent registered public accountant.

Based upon the review and discussions described in the preceding paragraph, our audit committee recommended to the board of directors that the audited financial statements of the Company be included in the Annual Report on Form 10-K for the year ended December 31, 2010 filed with the SEC.

Submitted by the Audit Committee of the Company s Board of Directors²:

Peter J. Pizzo, III (Chairman)
Calvin W. Roberts, M.D.
Glen Bradley, Ph.D.³

¹ The material in this report shall not be deemed to be soliciting material or filed with the SEC. This report shall not be deemed incorporated by reference into any of our other filings under the Exchange Act or the Securities Act of 1933, as amended, except to the extent the Company specifically incorporates it by reference into such filing.

² Anders D. Hove, M.D. resigned as a member of the audit committee effective as of April 18, 2011 and therefore did not sign this report.

³ Appointed as a member of the audit committee effective as of April 18, 2011.

Table of Contents**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The following table provides information concerning beneficial ownership of our common stock as of April 13, 2011, by:

each stockholder, or group of affiliated stockholders, known to us to beneficially own more than 5% of our outstanding common stock;

each of our named executive officers;

each of our directors; and

all of our current executive officers and directors as a group.

The table below is based upon information supplied by directors, executive officers and principal stockholders and Schedule 13Gs and 13Ds filed with the SEC through April 13, 2011.

The percentage ownership is based upon 31,333,483 shares of common stock outstanding as of April 13, 2011.

For purposes of the table below, we deem shares of common stock subject to options or warrants that are currently exercisable or exercisable within 60 days of April 13, 2011 to be outstanding and to be beneficially owned by the person holding the options or warrants for the purpose of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. Except as otherwise noted, the persons or entities in this table have sole voting and investing power with respect to all of the shares of common stock beneficially owned by them, subject to community property laws, where applicable.

Name and Address of Beneficial Owner(1)	Number of Shares Beneficially Owned	Percentage of Shares Beneficially Owned
5% Stockholders (other than our executive officers and directors)		
BAVP, LP 950 Tower Lane, Suite 700 Foster City, California 94404	4,863,094(2)	15.5%
Domain Associates, L.L.C. One Palmer Square Princeton, New Jersey 08542	4,877,477(3)	15.6%
Intersouth Partners 406 Blackwell Street, Suite 200 Durham, North Carolina 27701	4,877,480(4)	15.6%
Polaris Venture Partners 1000 Winter Street, Suite 3350 Waltham, Massachusetts 02451	4,877,481(5)	15.6%
Venrock Associates	3,949,070(6)	12.6%

2494 Sand Hill Road, Suite 200
Menlo Park, California 94025

Table of Contents

Name and Address of Beneficial Owner(1)	Number of Shares Beneficially Owned	Percentage of Shares Beneficially Owned
Directors and Named Executive Officers		
Mark J. Brooks	4,864,969(7)	15.5%
Susan Caballa	236,710(8)	*
Richard S. Eiswirth	264,328(9)	*
Kenneth Green, Ph.D.	349,623(10)	1.1%
Brian K. Halak, Ph.D.	4,879,352(11)	15.6%
David Holland	266,381(12)	*
Anders D. Hove, M.D.	3,950,945(13)	12.6%
C. Daniel Myers	542,429(14)	1.7%
Peter J. Pizzo, III	7,500(15)	*
Calvin W. Roberts, M.D.	374,277(16)	1.2%
Philip R. Tracy	4,879,355(17)	15.6%
Bryce Youngren	4,879,356(18)	15.6%
Glen Bradley, Ph.D.(19)		0%
All current directors and executive officers as a group (12 persons) (20)	21,544,280	65.8%

* Represents beneficial ownership of less than one percent of our outstanding common stock.

- (1) Unless otherwise indicated, the address for each beneficial owner is c/o Alimera Sciences, Inc., 6120 Windward Parkway, Suite 290, Alpharetta, Georgia 30005.
- (2) The general partner of BAVP, L.P. is Scale Venture Management I, LLC. The managing members of Scale Venture Management I, LLC share voting and investment power with respect to these shares. Mark J. Brooks, a member of our board of directors, is a managing member of Scale Venture Management I, LLC, and shares voting and investment power with the three other managing members of Scale Venture Management I, LLC. Mr. Brooks disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.
- (3) Represents 4,451,745 shares held by Domain Partners VI, L.P. and 47,704 shares held by DP VI Associates, L.P. The managing members of One Palmer Square Associates VI, L.L.C., the general partner of Domain Partners VI, L.P. and DP VI Associates, L.P., share voting and investment power with respect to these shares. Brian Halak, Ph.D., a member of our board of directors, is a member of One Palmer Square Associates VI, LLC, but has no voting or investment power and disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.
- (4) Represents 69,616 shares held by Intersouth Affiliates V, L.P.; 1,518,808 shares held by Intersouth Partners V, L.P.; 1,962,472 shares held by Intersouth Partners VI, L.P.; and 948,556 shares held by Intersouth Partners VII, L.P. Philip R. Tracy, a member of and the chairman of our board of directors, is a member of each of Intersouth Associates V, LLC, Intersouth Associates VI, LLC and Intersouth Associates VII, LLC. Pursuant to powers of attorney granted by each of Intersouth Associates V, LLC, Intersouth Associates VI, LLC and Intersouth Associates VII, LLC, Mr. Tracy shares voting power with respect to the securities owned by the entities for

which these entities serve as general partners. Mr. Tracy disclaims beneficial ownership of these shares held by Intersouth Affiliates V, L.P., Intersouth Partners V, L.P., Intersouth Partners VI, L.P., and Intersouth Partners VII, L.P., except to the extent of his pecuniary interest therein.

- (5) Represents 4,789,727 shares held by Polaris Venture Partners IV, L.P. and 87,754 shares held by Polaris Venture Entrepreneurs Fund IV, L.P. Polaris Venture Management Co., IV, L.L.C., is the sole general partner of Polaris Venture Partners IV, L.P. and Polaris Venture Partners Entrepreneurs Fund IV, L.P. Bryce Youngren, a member of our board of directors, has an assignee interest in Polaris Venture Management Co, IV, L.L.C. To the extent that he is deemed to share voting and investment powers with

Table of Contents

respect to the shares held by Polaris Venture Partners IV, L.P. and Polaris Venture Partners Entrepreneurs Fund IV, L.P., Mr. Youngren disclaims beneficial ownership of all such shares, except to the extent of his pecuniary interest therein.

- (6) Represents 2,965,404 shares held by Venrock Associates IV, L.P.; 604,737 shares held by Venrock Partners, L.P.; and 72,858 shares held by Venrock Entrepreneurs Fund IV, L.P. Venrock Management IV, LLC, Venrock Partners Management, LLC, and VEF Management IV, LLC are the sole general partners of Venrock Associates IV, L.P., Venrock Partners, L.P., and Venrock Entrepreneurs Fund IV, L.P., respectively. Venrock Management IV, LLC, Venrock Partners Management, LLC, and VEF Management IV, LLC disclaim beneficial ownership of all shares held by Venrock Associates IV, L.P., Venrock Partners, L.P., and Venrock Entrepreneurs Fund IV, L.P., except to the extent of their pecuniary interest therein. Anders D. Hove, M.D., a member of our board of directors, is a member of each of Venrock Management IV, LLC, Venrock Partners Management, LLC, and VEF Management IV, LLC. Dr. Hove disclaims beneficial ownership of all shares held by Venrock Associates IV, L.P., Venrock Partners, L.P., and Venrock Entrepreneurs Fund IV, L.P. and beneficially owned by Venrock Management IV, LLC, Venrock Partners Management, LLC, and VEF Management IV, LLC, except to the extent of his pecuniary interest therein.
- (7) Mr. Brooks is a managing member of Scale Venture Management I, LLC, the general partner of BAVP, LP. Mr. Brooks is one of four managing members of Scale Venture Management I, LLC who share voting and investment power with respect to these shares. Mr. Brooks disclaims beneficial ownership of the shares held by BAVP, LP referenced in footnote (2) above, except to the extent of his pecuniary interest therein. Includes 1,875 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011.
- (8) Includes 184,272 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011.
- (9) Includes 263,319 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011.
- (10) Includes 349,623 shares issuable upon exercise of options exercisable with 60 days of April 13, 2011.
- (11) Dr. Halak is affiliated with Domain Associates L.L.C. Dr. Halak disclaims beneficial ownership of the shares held by the entities affiliated with Domain Associates referenced in footnote (3) above, except to the extent of his pecuniary interest therein. Includes 1,875 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011.
- (12) Includes 148,353 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011.
- (13) Dr. Hove is affiliated with Venrock Associates. Dr. Hove disclaims beneficial ownership of the shares held by the entities affiliated with Venrock Associates referenced in footnote (6) above, except to the extent of his pecuniary interest therein. Includes 1,875 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011. Dr. Hove resigned as a member of the board of directors effective April 18, 2011.
- (14) Includes 393,165 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011. Includes 149,264 shares held in joint tenancy with Mr. Myers spouse and pledged or held in a margin account with a brokerage firm.
- (15) Includes 5,000 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011.
- (16) Includes 28,347 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011, 39,706 shares issuable upon exercise of warrants exercisable within 60 days of April 13, 2011, and

88,187 shares held in trust with indirect ownership.

- (17) Mr. Tracy is affiliated with Intersouth Partners. Mr. Tracy disclaims beneficial ownership of the shares held by the entities affiliated with Intersouth Partners referenced in footnote (4) above, except to the extent of his pecuniary interest therein. Includes 1,875 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011.
- (18) Mr. Youngren is affiliated with Polaris Venture Partners. Mr. Youngren disclaims beneficial ownership of the shares held by the entities affiliated with Polaris Venture Partners referenced in footnote (5) above, except to the extent of his pecuniary interest therein. Includes 1,875 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011.

Table of Contents

- (19) Appointed as a member of the board of directors effective April 18, 2011.
- (20) Includes 1,379,579 shares issuable upon exercise of options exercisable within 60 days of April 13, 2011, 39,706 shares issuable upon of a warrant exercisable within 60 days of April 13, 2001, 88,187 shares held in trust with indirect ownership, and 149,264 shares held in joint tenancy by an executive and his spouse and pledged or held in a margin account with a brokerage firm. Excludes Anders D. Hove, M.D. due to his resignation as a member of the board of directors effective April 18, 2011.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act requires our directors, executive officers, and certain holders of more than 10% of our common stock to file reports regarding their ownership and changes in ownership of our securities with the SEC and to furnish us with copies of all Section 16(a) reports that they file.

Based solely upon a review of Forms 3 and 4 and amendments thereto furnished to us and written representations provided to us by all of our directors and executive officers and certain of our greater than 10% stockholders, we believe that during the year ended December 31, 2010, our directors, executive officers, and greater than 10% stockholders complied with all applicable Section 16(a) filing requirements.

Table of Contents

CERTAIN RELATIONSHIPS AND RELATED PERSONS TRANSACTIONS

In addition to the compensation arrangements with directors and executive officers described elsewhere in this proxy statement, the following is a description of transactions since January 1, 2010, in which we have been a participant, in which the amount involved exceeded or will exceed \$120,000 and in which any of our directors, executive officers, beneficial holders of more than 5% of our capital stock, or entities affiliated with them, had or will have a direct or indirect material interest.

All of the transactions set forth below were approved by a majority of our board of directors, including a majority of the independent and disinterested members of our board of directors. We believe that we have executed all of the transactions set forth below on terms no less favorable to us than we could have obtained from unaffiliated third-parties. It is our intention to ensure that all future transactions between us and our directors, executive officers and principal stockholders and their affiliates are approved by a majority of the members of our board of directors, including a majority of the independent and disinterested members of our board of directors, and are on terms no less favorable to us than those that we could obtain from unaffiliated third-parties.

Transactions with our Directors, Executive Officers, Key Employees and Significant Stockholders.

Indemnification Agreements. We have entered into indemnification agreements with each of our directors and executive officers and certain other key employees. The agreements provide that we will indemnify each of our directors, executive officers and such key employees against any and all expenses incurred by that director, executive officer or key employee because of his or her status as one of our directors, executive officers or key employees to the fullest extent permitted by Delaware law, our restated certificate of incorporation and our amended and restated bylaws (except in a proceeding initiated by such person without board approval). In addition, the agreements provide that, to the fullest extent permitted by Delaware law, we will advance all expenses incurred by our directors, executive officers and key employees in connection with a legal proceeding in which they may be entitled to indemnification.

Stock Option Awards. See Corporate Governance Director Compensation and Executive Compensation for additional information regarding stock options and stock awards granted to our directors and named executive officers.

Table of Contents**EXECUTIVE OFFICERS**

Set forth below is the name, age, and position of each of our executive officers as of April 13, 2011 and certain biographical information for each executive officer.

Name	Age	Position
C. Daniel Myers	56	President, Chief Executive Officer and Director
Richard S. Eiswirth	42	Chief Financial Officer and Chief Operating Officer
Kenneth Green, Ph.D.	52	Senior Vice President and Chief Scientific Officer
Susan Caballa	66	Senior Vice President, Regulatory and Medical Affairs
David Holland	47	Senior Vice President of Sales and Marketing

C. Daniel Myers For biographical information, see Proposal 1 Election of Directors Nominees for Election as Class I Directors at the Annual Meeting.

Richard S. Eiswirth has served as Chief Financial Officer of our Company since October 2005 and as Chief Operating Officer since August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as chief financial officer and senior executive vice president of Netzee, Inc., a provider of Internet banking solutions to community banks from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth currently serves as chairman, audit committee chairman and member of the compensation committee of Jones Soda Co., a Seattle, Washington based beverage company, and previously served as director and audit committee chairman of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a Certified Public Accountant in Georgia. Mr. Eiswirth holds a Bachelor's in accounting from Wake Forest University.

Kenneth Green, Ph.D. joined us in 2004 as Vice President of Scientific Affairs, and has served as the Senior Vice President and Chief Scientific Officer of our Company since January 2007. Prior to joining us, Dr. Green served as the V.P. Global Head of Clinical Sciences at Novartis Ophthalmics. He has managed ophthalmic clinical development organizations at Storz Ophthalmics, Bausch & Lomb and CIBA Vision. He started his career in the pharmaceutical industry in 1984, as a basic research scientist in drug discovery at Lederle Laboratories, and has since held positions in many areas of drug development. Dr. Green holds a B.A. in Chemistry from Southern Illinois University and a Ph.D. in Organic Chemistry from Ohio State University.

Susan Caballa has served as the Senior Vice President of Regulatory and Medical Affairs of our Company since 2004. Prior to joining us, Ms. Caballa served as the Vice President of Regulatory and Medical Affairs at Novartis Ophthalmics from 1999 to 2004. Ms. Caballa also held various regulatory management positions with the following companies engaged in the development and marketing of ophthalmic products: Allergan, Inc. (1983-1987), Iolab Corporation, a J&J Company (1987-1994) and Alcon Laboratories, Inc. (1994-1999). Ms. Caballa holds a B.S. in Chemistry and a Masters in Chemistry from the University of Santo Tomas and University of the Philippines.

David Holland is one of our co-founders and has served as the Vice President of Marketing since the founding of our Company in 2003. Mr. Holland has served as the Senior Vice President of Sales and Marketing since August 2010. Prior to founding our Company, Mr. Holland served as the Vice President of Marketing of Novartis Ophthalmics from

1998 to 2003. In 1997, Mr. Holland served as Global Head of the Lens Business at CIBA Vision and in 1996, Global Head of the Lens Care Business of CIBA Vision. From 1992 to 1995, Mr. Holland served as the Director of Marketing for CIBA Vision Ophthalmics. From 1989 to 1991, Mr. Holland served as New Products Manager for CIBA Vision. From 1985 to 1989, Mr. Holland served as a Brand Assistant and Assistant Brand Manager of Procter and Gamble. Mr. Holland holds an A.B. in Politics from Princeton University.

Election of Officers

Our executive officers are currently elected by our board of directors on an annual basis and serve until their successors are duly elected and qualified, or until their earlier resignation or removal. There are no family relationships among any of our directors or executive officers.

Table of Contents

EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

This section discusses our executive compensation policies and decisions and the most important factors relevant to an analysis of these policies and decisions. It provides qualitative information regarding the manner and context in which compensation is awarded to and earned by our named executive officers and offers perspective on the data presented in the tables and narrative that follow.

Executive Summary of 2010 Executive Compensation Program

The following provides a brief overview of the more detailed disclosure set forth in this Compensation Discussion and Analysis.

2010 was an important year in the Company's history with numerous milestones having been achieved, including the completion of our initial public offering (IPO) and the submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for ILUVIEN in the treatment of diabetic macular edema.

On January 1, 2010, the salaries of our named executive officers were increased based on the progress of our clinical programs and the efforts made by our named executive officers in preparing and positioning our Company for the IPO and the NDA.

On December 16, 2009, the target bonus, corporate goals and individual goals for the 2010 annual incentive compensation of our named executive officers were approved.

Effective August 2010, Mr. Eiswirth was promoted to Chief Operating Officer in addition to continuing as our Chief Financial Officer and Mr. Holland was promoted to Senior Vice President of Sales and Marketing. As a result of these promotions, Mr. Eiswirth's 2010 annual salary was increased by \$39,416 and Mr. Holland's annual salary was increased by \$45,864.

In January 2011, the compensation committee determined that certain of the corporate goals under the 2010 annual incentive compensation program for our named executive officers were fully or partially achieved, including the completion of our IPO, the submission of a NDA for ILUVIEN and preparation for a potential commercial launch of ILUVIEN in the U.S., and accordingly the named executive officers were each awarded 70% of the portion of their respective annual incentive compensation that was based on the Company's corporate goals.

Additionally, in January 2011, the compensation committee determined the extent to which our Chief Executive Officer had met or exceeded his individual goals for 2010 and awarded him 82% of his annual incentive compensation that was based on those goals. Further, the compensation committee determined the extent as to which our other named executives met or exceeded their respective individual goals for 2010 based on the recommendations of our Chief Executive Officer and awarded our other named executives 83.5% to 100% of the annual incentive compensation that was based on such officer's respective goals.

Compensation Philosophy and Objectives

As a biopharmaceutical company, we operate in an extremely competitive, rapidly changing and heavily regulated industry. We believe that the skill, talent, judgment and dedication of our executive officers and other key employees are critical factors affecting our long-term stockholder value. Therefore, our goal is to maintain a compensation program that will fairly compensate employees, attract and retain highly qualified employees, motivate the performance of employees towards, and reward the achievement of, clearly defined corporate goals, and align employees' long-term interests with those of our stockholders. To that end, our executive officers' compensation has four primary components: (1) base compensation or salary, (2) annual incentive compensation or bonus, (3) long-term incentive compensation in the form of stock option or other equity awards and (4) certain cash and equity award vesting acceleration benefits in the event of an executive

Table of Contents

officer's involuntary termination without cause. In addition, we provide our executive officers a variety of benefits that are available generally to all salaried employees.

We review the total compensation of our executive officers when making compensation decisions. Although we view the components of our executive officers' compensation as related, we do not believe that the level of compensation derived from one component of compensation should proportionately increase, decrease, or negate compensation from other components. Our executive officer compensation philosophy is to (1) provide overall compensation, when targeted levels of performance are achieved, which allows us to attract and retain highly qualified employees and (2) emphasize at-risk equity compensation over annual cash compensation to retain officers and align a substantial portion of their compensation with long-term stockholders' interests. Our annual cash incentives and our stock option awards are aligned with our achievement of corporate strategic and operating goals. We believe that successful execution against goals is the best way to enhance long-term stockholder value.

We historically determined the appropriate level for each compensation component based in part, but not exclusively, on a review of various survey and publicly available compensation data, our view of internal equity and consistency, our overall performance and other considerations we deem relevant. For annual compensation reviews we evaluate each executive's performance, look to industry trends in compensation levels and generally seek to ensure that compensation is appropriate for an executive's level of responsibility and for promotion of future performance. Except as described below, we have not adopted any formal or informal policies or guidelines for allocating compensation between long-term and short-term compensation, between cash and non-cash compensation or among different forms of non-cash compensation. However, our philosophy is to make a greater percentage of an employee's compensation performance-based and to keep cash compensation to a nominally competitive level while providing the opportunity to be well rewarded through equity if we perform well over time. We also believe that for life science companies, stock-based compensation is a significant motivator in attracting employees, and while base salary and the potential for cash bonuses must be at competitive levels, performance is most significantly impacted by appropriately relating the potential for creating stockholder value to an individual's compensation potential through the use of equity awards.

We do not have stock ownership guidelines for our executive officers, because the compensation committee is satisfied that stock and option holdings among our executive officers are sufficient at this time to provide motivation and to align this group's interests with those of our stockholders. In addition, we believe that stock ownership guidelines are rare in development-stage biopharmaceutical companies, which means that ownership requirements would put us at a competitive disadvantage when recruiting and retaining high-quality executives. Under our trading policy, we prohibit all hedging or short sales involving our securities by our executive officers and employees.

Compensation Committee

The compensation committee of our board of directors is currently comprised of three non-employee members of the board of directors. The compensation committee's basic responsibility is to review the performance of our management in achieving corporate objectives and to ensure that the executive officers are compensated effectively in a manner consistent with our compensation philosophy and competitive practice. In fulfilling this responsibility, the compensation committee reviews the performance of each executive officer each year. Our Chief Executive Officer, as the manager of the executive team, assesses the executives' contributions to the corporate goals and makes a recommendation to the compensation committee with respect to any merit increase in salary, cash bonus and equity award for each member of the executive team. The compensation committee meets with the Chief Executive Officer to evaluate, discuss and modify or approve these recommendations. The compensation committee also conducts a similar evaluation of the Chief Executive Officer's contributions when the Chief Executive Officer is not present, and determines any increase in salary, cash bonus and annual equity award.

Table of Contents***Compensation Consultant***

Prior to the third quarter of 2010, the compensation committee had not engaged a compensation consultant for advice on matters related to compensation for executive officers, other key employees and non-employee directors. In July 2010, the compensation committee determined that, in light of Company's initial public offering, it would engage an executive compensation consultant to review the compensation of the Company's executives and advise the compensation committee with respect to any recommended changes to such compensation. The compensation committee engaged Hewitt Associates in the third quarter of 2010 to provide advice in connection with the 2011 compensation program for the Company's executive officers. The compensation committee utilized Hewitt Associates recommendations in connection with the equity grants to the named executive officers in November of 2010 and setting the named executive officers' 2011 base salary and target bonus.

Peer Group

In late 2007, the compensation committee identified a group of peer companies to use to prepare an analysis of competitive compensation data. The compensation committee continues to review and revise the peer group periodically to ensure that it reflects companies similar to us in size and development stage. Our peer group utilized to prepare data in connection with 2010 compensation decisions, which is listed below, was selected by the compensation committee in late 2009, based on a review of biopharmaceutical companies that were similar to us in market capitalization, development stage and business model.

Achillion	Inhibitex	Pharmasset
Aegerion	MAP	Synta
Amicus	Neurogesx	Targacept
Cadence Pharmaceuticals	Orexigen	Vanda
Cardiovascular Systems (f/k/a Replidyne)		

Historically, as our compensation committee makes decisions with respect to compensation for individual executive officers and for the Company's compensation programs in general, it relied upon the peer group or survey data to understand where the Company's compensation practices fall relative to its competitors, to identify individual officers whose compensation seems out of step with other Company officers or similar officers at peer group or similar companies, and as a way of staying current with market practices. Prior to the fourth quarter of 2010, the compensation committee had not specifically benchmarked or targeted a particular level of compensation with respect to total compensation or to any individual component of compensation and the objective peer group or survey market data was one of the numerous factors the compensation committee uses to assist its decision making process.

In the fourth quarter of 2010, the compensation committee determined that it would begin targeting the compensation of our executive officers based on the compensation provided to executives in similar positions in peer group companies. The compensation committee decided to begin targeting overall compensation at or near the 50th percentile of its peer group companies while continuing to follow its historical philosophy of placing greater emphasis on long-term compensation in an effort to align our executive officers' interests with those of our stockholders. As such, the compensation committee decided to begin setting our named executive officers' base salary at or near the 25th percentile of its peer group, annual incentive compensation at or near the 50th percentile and long-term incentive compensation in such a manner that the executives total annual compensation would be at or near the 50th percentile of the Company's peer group. The compensation committee believes this practice will allow us to retain and attract executive talent while maintaining the desired emphasis on long term incentives aligned with stockholders. The compensation committee utilized this new approach in November of 2010 when it granted stock

options to our named executive officers and set their 2011 base salary and target bonus. The peer group companies examined in connection with these decisions was identified by the compensation committee with the assistance of Hewitt Associates and differed from the peer group reviewed by the compensation committee when it set 2010 compensation.

Table of Contents

In certain circumstances in which an executive officer is uniquely critical to our success or due to the intensely competitive market for highly qualified employees in our industry, the compensation committee expects that it may determine to deviate from this new approach. The compensation committee will continue to review the method utilized for compensation decisions on an ongoing basis.

Principal Elements of Compensation

Base Salaries. Base salaries are set to reflect compensation commensurate with the individual's current position and work experience. Our goal in this regard is to attract and retain high-caliber talent for the position and to provide a base wage that is not subject to performance risk. Prior to 2008, our competitive analysis was primarily based upon salary surveys publicly available to us, or made available to us based upon our participation in the survey. Beginning in late 2007, for purposes of determining the executive salaries for 2008, the competitive market analysis was made by a comparison to our then current peer group.

Salary for our Chief Executive Officer and the other executive officers was historically established based on the underlying scope of their respective responsibilities, taking into account, among other things, competitive market compensation data. We review base salaries for the executive officers annually near the end of each year, and our Chief Executive Officer proposes salary adjustments (other than for himself) to the compensation committee based on any changes in our competitive market salaries, individual performance and/or changes in job duties and responsibilities. The compensation committee then determines any salary adjustment percentage applicable to the executive officers.

In January 2010, as part of the annual compensation review and as part of our planning to undertake our IPO, the compensation committee reviewed the compensation of our executive team and determined that based on each named executive officer's individual contributions, the progress of our clinical programs and the efforts made by our named executive officers in preparing and positioning our Company for the IPO and the submission of a NDA for ILUVIEN in the treatment of diabetic macular edema that it was in our Company's best interest to increase the 2010 base salary of our named executive officers, including our Chief Executive Officer as follows:

	2009	2010
C. Daniel Myers	\$ 353,600	\$ 367,744
Richard S. Eiswirth	\$ 249,600	\$ 259,584
Kenneth Green, Ph.D.	\$ 260,000	\$ 270,400
Susan Caballa	\$ 228,800	\$ 237,952
David Holland	\$ 218,400	\$ 227,136

The base salary increase for Mr. Myers was in recognition of his performance as Chief Executive Officer of our Company, the significant progress made towards meeting the Company's strategic goals, management of the Company's fiscal resources. Mr. Eiswirth's base salary was increased primarily due to his efforts implementing corporate expense controls and the enhancements made to our Company's financial infrastructure in anticipation of our IPO. Dr. Green's and Ms. Caballa's base salary was increased due to their respective contributions to the successful progression of our clinical programs, most notably ILUVIEN. The base salary increase for Mr. Holland was primarily due to his expansion of our sales and marketing infrastructure in anticipation of the potential commercial launch of ILUVIEN.

On August 11, 2010, the Company promoted Mr. Eiswirth to Chief Operating Officer and David R. Holland to Senior Vice President of Sales and Marketing. In addition to his new role, Mr. Eiswirth retained his position as the Company's

Chief Financial Officer. As a result of these promotions, Mr. Eiswirth's 2010 base salary was increased to \$299,000 and Mr. Holland's base salary was increased to \$273,000.

Annual Incentive Compensation. Annual cash incentives for the executive officers are designed to reward the achievement of overall performance by our executives each year, which we believe should increase stockholder value. Annual incentive awards are determined and paid out based upon the following criteria:

50% based upon the achievement of individual performance goals;

Table of Contents

25% based upon our achievement of corporate performance goals; and

25% based upon the subjective assessment by the compensation committee of the progress of the executive team towards our strategic objectives.

The annual performance goals, both corporate and individual, are established during the first quarter of the fiscal year and are clearly communicated and measurable. An aggregate target bonus, which includes the potential subjective or discretionary bonus, is set for each executive officer based in part on our review of our peer group and other publicly available market data and is stated in terms of a percentage of the executive officer's annualized base salary for the year. The target bonus for our Chief Executive Officer in 2010 was 40% of his annualized base salary, and 25% of annualized base salary for each of the other named executive officers.

Early each year, the executive team proposes a set of corporate performance objectives and proposes percentage weights to be allocated to each goal, with higher weights given to those goals that we believe will have a greater impact on our value and/or are more challenging to achieve within the time frame specified. The compensation committee evaluates the goals and weightings and makes a recommendation to the board of directors for approval. The individual goals of our Chief Executive Officer and other named executive officers are established in a manner intended to align their performance objectives with, and support the achievement of, our corporate performance goals. Our Chief Executive Officer proposes his annual individual performance goals and percentage weights to the compensation committee for its consideration and approval. The performance goals and percentage weights of the remaining named executive officers are determined individually by the Chief Executive Officer and the specific named executive and then approved by the compensation committee.

At the end of each year, our Chief Executive Officer assesses his and the named executive officers' achievement of their individual performance goals for the year, and recommends a percentage payout for each individual for the 50% of the target bonus that is allocated to individual performance goals. The compensation committee accepts and approves that percentage as is, or adjusts it to the extent the compensation committee deems appropriate. Our Chief Executive Officer and his management team also assess our achievement of corporate performance goals, and recommend a percentage payout for the 25% of the target bonus that is allocated to corporate performance goals. The compensation committee accepts and approves that percentage as is, or adjusts it to the extent the compensation committee deems appropriate. The remaining 25% of the annual incentive compensation is determined at the discretion of the compensation committee. The compensation committee evaluates subjective criteria, including, but not limited to, its assessment of the management team's stewardship of our Company, contributions to improving stockholder value, and strategic planning for long-term goals. Our compensation committee believes that partial or over achievement of both corporate and individual goals is possible.

2010 Annual Incentive Compensation. With input from our Chief Executive Officer, our compensation committee approves corporate and individual performance goal achievement for each of our named executive officers. In January 2011, our compensation committee reviewed the recommendations of our Chief Executive Officer with respect to the achievement of our 2010 corporate goals and the 2010 individual goals of our named executives and determined that bonuses moderately below the target level should be paid to all of our named executive officers based on the exceptional progress of our clinical programs and the efforts made by our named executive officers in connection with, among other things, the submission of a NDA for the use of ILUVIEN in the treatment of diabetic macular edema, our IPO and the preparation for the potential commercial launch of ILUVIEN.

Table of Contents

2010 Corporate Goals. For 2010, the corporate goals component of the annual performance goals under our Incentive Compensation Bonus Plan, which accounted for 25% of the amount of bonus potential for each of our named executive officers, the weighting of each goal, and our compensation committee's quantitative assessment of the degree to which each goal was actually achieved, were as follows:

Corporate Goal	Weighted Percentage	Weighted Percentage Achievement
Execution of road show for Company's IPO resulting in successful IPO	35%	30%(1)
FDA acceptance of NDA for ILUVIEN in the treatment of diabetic macular edema	25%	25%(2)
Receipt of FDA approval of NDA for ILUVIEN in the treatment of diabetic macular edema	25%	0%(3)
Preparation for potential U.S. commercial launch of ILUVIEN		
Hire three (3) medical science liaisons	5%	5%(4)
Submit application for current procedural terminology (CPT) code for ILUVIEN to the American Medical Association	5%	5%(5)
Hire managed care director	5%	5%(6)
Total	100%	70%

- (1) The Company's IPO of 6,550,000 shares of common stock at an initial price to the public of \$11.00 per share closed on April 27, 2010 resulting in net proceeds to the Company of approximately \$68,395,000. However, the Company had desired to sell 6,000,000 shares of common stock at initial price to public of \$15.00 to \$17.00 per share.
- (2) The FDA accepted our NDA filing for ILUVIEN in the treatment of diabetic macular edema with priority review status on August 30, 2010.
- (3) The Company received a Complete Response Letter (CRL) from the FDA in the latter half of December 2010 which communicated the FDA's decision that the NDA for ILUVIEN could not be approved in its present form.
- (4) The Company engaged a contract organization to provide us three medical science liaisons in July of 2010.
- (5) The Company received input from the Retina Advisory Boards that the CPT code 67028 was accepted.
- (6) The Company hired a managed care director in August of 2010.

2010 Individual Goals. The individual goals component of the annual performance goals under our Incentive Compensation Bonus Plan for our named executive officers are primarily related to the corporate goals for which they are most responsible and, to a lesser extent, individual development or department specific goals, subject to discretionary adjustments that our compensation committee deems appropriate. Our Chief Executive Officer makes recommendations to our compensation committee as to the degree to which those named executive officers have satisfied their individual goals. For 2010, the individual goals component of the annual performance goals under our Incentive Compensation Bonus Plan, which accounted for 50% of the amount of bonus potential for each of our named executive officers, the weighting of each goal, and our

Table of Contents

compensation committee's quantitative assessment of the degree to which each goal was actually achieved, were as follows:

	Goals	Weighted Percentage	Weighted Percentage Achievement
C. Daniel Myers	Execution of road show for Company's IPO resulting in successful IPO.	40%	40%(1)
	FDA acceptance of NDA with priority review status for ILUVIEN in the treatment of diabetic macular edema. FDA approval of NDA for ILUVIEN in the treatment of diabetic macular edema.	30%	15%(2)
	Submit and receive acceptance of Marketing Authorization Application (MAA) for ILUVIEN in Europe.	5%	5%(3)
	Coordinate the execution of a successful sales and marketing strategy resulting in an organizational structure that is prepared for the commercial launch of ILUVIEN.	20%	20%(4)
	Manufacture and validate first commercial batches of ILUVIEN.	5%	2%(5)
	Total	100%	82.0%

- (1) The Company's IPO of 6,550,000 shares of common stock at an initial price to the public of \$11.00 per share closed on April 27, 2010 resulting in net proceeds to the Company of approximately \$68,395,000. Although the Company had desired to sell 6,000,000 shares of common stock at an initial price to the public of \$15.00 to \$17.00 per share, the compensation committee determined that Mr. Myers' individual performance in completing the Company's IPO merited 100% achievement of this goal.
- (2) The FDA accepted our NDA filing for ILUVIEN in the treatment of diabetic macular edema with priority review status on August 30, 2010, however, the Company received a Complete Response Letter (CRL) from the FDA in the latter half of December 2010 which communicated the FDA's decision that the NDA for ILUVIEN could not be approved in its present form.
- (3) In July 2010, the Company submitted a MAA for ILUVIEN to the Medicines and Healthcare products Regulatory Agency in the United Kingdom and to regulatory authorities in Austria, France, Germany, Italy, Portugal and Spain.
- (4) In anticipation of the potential U.S. commercial launch of ILUVIEN following FDA approval, the Company believes that the necessary sales and marketing infrastructure was created during 2010. The Company has engaged an advertising agency, a public relations firm, an investor relations agency and a contract sales organization in preparation of the potential commercial launch of ILUVIEN.
- (5) The initiation of the manufacturing of the first commercial batches of ILUVIEN commenced as scheduled. However, the manufacturing process was delayed due to a component redesign.

	Goals	Weighted Percentage	Weighted Percentage Achievement
Richard S. Eiswirth	Manage pre-IPO strategic transaction process, coordinate diligence efforts and evaluate sale of the Company as a strategic option.	10%	10%(1)
	Coordinate IPO effort. Coordinate filing of necessary amendments to the Company's registration statement on Form S-1. Manage the Company's relationship with the underwriters of its IPO. Complete IPO.	50%	50%(2)
	Establish financial reporting process for the Company's post-IPO filing requirements. Complete and timely file all required Company reports with the SEC.	20%	20%(3)
	Investigate, evaluate and provide alternate financing solutions to our board of directors.	20%	20%(4)
	Total	100%	97.0%(5)

Table of Contents

- (1) The Company determined to proceed with its IPO rather than pursue a strategic transaction.
- (2) The Company's IPO of 6,550,000 shares of common stock at an initial price to the public of \$11.00 per share closed on April 27, 2010 resulting in net proceeds to the Company of approximately \$68,395,000. Although the Company had desired to sell 6,000,000 shares of common stock at an initial price to the public of \$15.00 to \$17.00 per share, the compensation committee determined that Mr. Eiswirth's efforts in connection with updating the Company's registration statement, coordinating the IPO process and managing the Company's relationship with the underwriters of its IPO significantly contributed to the Company's completion of its IPO on the schedule determined by our board of directors.
- (3) Following the Company's IPO, all of the Company's required filings in 2010 were made on a timely basis in accordance with SEC rules and regulations.
- (4) In October 2010, the Company entered into (i) a Loan and Security Agreement with Silicon Valley Bank and MidCap Financial LLP (Term Loan) under which the Company may borrow up to \$12,500,000, subject to certain terms and conditions and (ii) a Loan and Security Agreement with Silicon Valley Bank (Revolving Loan Agreement), pursuant to which the Company obtained a secured revolving line of credit from Silicon Valley Bank with borrowing availability up to \$20,000,000, subject to certain terms and conditions.
- (5) The compensation committee determined that the individual corporate goal component of Mr. Eiswirth's 2010 annual incentive compensation should be reduced by 3% given the fact that the manufacture and validation of the first commercial batches of ILUVIEN were not completed in 2010. The initiation of the manufacturing of the first commercial batches of ILUVIEN commenced as scheduled. However, the manufacturing process was delayed due to a component redesign.

	Goals	Weighted Percentage	Weighted Percentage Achievement
Kenneth Green, Ph.D.	Submit NDA for ILUVIEN in the treatment of diabetic macular edema.	5%	5%(1)
	FDA acceptance of NDA for ILUVIEN in the treatment of diabetic macular edema	15%	15%(2)
	File MAA for ILUVIEN in the United Kingdom.	10%	10%(3)
	FDA grant of priority review status of NDA for ILUVIEN in the treatment of diabetic macular edema.	15%	15%(2)
	FDA approval of NDA for ILUVIEN in the treatment of diabetic macular edema.	25%	12.5%(4)
	Manage Company's clinical programs and budget to within 10% of target approved by our board of directors.	30%	30%(5)
	Total		100%

(1)

In late June 2010, the Company submitted the NDA filing for ILUVIEN in the treatment of diabetic macular edema.

- (2) The FDA accepted our NDA filing for ILUVIEN in the treatment of diabetic macular edema with priority review status on August 30, 2010.
- (3) In July 2010, the Company submitted a MAA for ILUVIEN to the Medicines and Healthcare products Regulatory Agency in the United Kingdom and to regulatory authorities in Austria, France, Germany, Italy, Portugal and Spain.
- (4) The Company received a Complete Response Letter (CRL) from the FDA in the latter half of December 2010 whereby the FDA communicated its decision that the NDA for ILUVIEN could not be approved in its present form. The compensation committee determined that although this individual goal was not satisfied during 2010, Dr. Green should be awarded 50% of the incentive bonus attributable to this goal. This decision was based on the compensation committee's determination that despite the fact that the

Table of Contents

FDA did not approve the NDA, Dr. Green had managed the clinical research and development process in an exceptional manner and that the items raised in the CRL were beyond Dr. Green's control.

- (5) The compensation committee determined that the Company's clinical program expenditures were within 10% of the targeted budget.

	Goals	Weighted Percentage	Weighted Percentage Achievement
Susan Caballa	Submit NDA for ILUVIEN in the treatment of diabetic macular edema.	5%	5%(1)
	FDA acceptance of NDA for ILUVIEN in the treatment of diabetic macular edema	15%	15%(2)
	FDA grant of priority review status of NDA for ILUVIEN in the treatment of diabetic macular edema.	10%	10%(2)
	Submit MAA for ILUVIEN in the United Kingdom and six other European Union Countries	5%	5%(3)
	Acceptance of MAA for ILUVIEN in the United Kingdom and six other European Union Countries	10%	10%(4)
	Engineering/scale-up at Alliance Medical Inc. to demonstrate ability to manufacture 800-unit batches; data and report written in support of the pre-approval inspection.	5%	6%(5)
	Facilitate successful pre-approval inspection at Alliance Medical Inc.	10%	10%(6)
	FDA approval of NDA for ILUVIEN in the treatment of diabetic macular edema.	35%	17.5%(7)
	Start manufacture and validation of first commercial batches of ILUVIEN.	5%	5%(8)
	Total	100%	83.5%

- (1) In late June 2010, the Company submitted the NDA filing for ILUVIEN in the treatment of diabetic macular edema.
- (2) The FDA accepted our NDA filing for ILUVIEN in the treatment of diabetic macular edema with priority review status on August 30, 2010.
- (3) In July 2010, the Company submitted a MAA for ILUVIEN to the Medicines and Healthcare products Regulatory Agency in the United Kingdom and to regulatory authorities in Austria, France, Germany, Italy, Portugal and Spain.
- (4) The MAA submissions in the United Kingdom, Austria, France, Germany, Italy, Portugal and Spain were accepted.
- (5)

The compensation committee determined that Ms. Caballa over achieved on this individual goal due to the fact that scale up for manufacture of commercial batches of ILUVIEN was two months ahead of schedule.

- (6) The compensation committee determined that the NDA portion of the pre-approval inspection was successful.
- (7) The Company received a Complete Response Letter (CRL) from the FDA in the latter half of December 2010 whereby the FDA communicated its decision that the NDA for ILUVIEN could not be approved in its present form. The compensation committee determined that although this individual goal was not satisfied during 2010, Ms. Caballa should be awarded 50% of the incentive bonus attributable to this goal. This decision was based on the compensation committee's determination that despite the fact that the FDA did not approve the NDA, Ms. Caballa had managed the regulatory process in an exceptional manner and that the items raised in the CRL were beyond Ms. Caballa's control.
- (8) The initiation of the manufacturing of the first commercial batches of ILUVIEN commenced as scheduled.

Table of Contents

	Goals	Weighted Percentage	Weighted Percentage Achievement
David Holland	Manage and execute corporate communication strategy.	5%	5%(1)
	Establish marketing organization including personnel, agencies, and develop strategic marketing plan.	40%	40%(2)
	Establish sales organization structure.	10%	12%(3)
	Execute pricing, reimbursement and market access strategy in advance of ILUVIEN launch.	20%	20%(4)
	Develop U.S. distribution strategy.	5%	5%(5)
	Determine and recommend sales/distribution/access strategy in Canada.	5%	4%(6)
	Determine commercial strategy for sales of ILUVIEN in the European Union.	5%	4%(7)
	Establish and maintain budget control in connection with product launch.	5%	5%(8)
	Create U.S. packaging for ILUVIEN for submission to the FDA.	5%	5%(9)
	Total		100%

- (1) The Company presented or was represented at over seven retina/ophthalmic meetings, disseminated 13 investor relations releases and eight press releases in 2010, redesigned its corporate website and established an investor relations presence.
- (2) The Company built its marketing organization, established its launch plan and would have been prepared for a commercial launch of ILUVIEN in the U.S. in the first quarter of 2011 had the FDA approved the Company's NDA in late 2010.
- (3) The Company engaged a contract sales organization (CSO), hired regional sales directors, recruited 29 sales reps in concert with the CSO and developed a sales training program in preparation for a commercial launch of ILUVIEN in the U.S. in the first quarter of 2011 had the FDA approved the Company's NDA in late 2010. The compensation committee determined that Mr. Holland had over achieved this goal primarily based upon the decision to utilize a CSO which mitigated the Company's financial risk associated with building a sales team prior to the approval of ILUVIEN.
- (4) The Company hired an experienced director of managed care, wrote draft AMCP dossiers and HEOR models, and developed a reimbursement hotline, co-pay assistance and patient assistance programs in preparation for a commercial launch of ILUVIEN in the U.S. in the first quarter of 2011 had the FDA approved the Company's NDA in late 2010.
- (5) The Company has finalized its U.S. distribution strategy for ILUVIEN and as of the end of 2010 was in contract negotiation with potential distributors.
- (6)

The Company determined to place its Canadian sales and distribution plan on hold after not receiving priority review from the Patented Medicine Prices Review Board of Canada. Therefore, the compensation committee determined that this corporate goal was partially achieved.

- (7) During 2010, representatives of the Company met with numerous companies regarding potential European commercial relationships. The compensation committee decided that Mr. Holland should be awarded 80% of the incentive award allotted to this goal based on the Company's progress in developing a European strategy.
- (8) The compensation committee believes that the budget control goal was completed and resulted in savings to the Company.
- (9) The Company completed the U.S. packaging for ILUVIEN which was included in the submission to the FDA in June 2010.

Table of Contents

2010 Discretionary Bonus. The remaining 25% of the amount of bonus potential for each of our named executive officers is awarded in the discretion of our compensation committee. In 2010, based on the level that our named executive officers achieved with regard to both the corporate and individual goals, including with respect to our clinical programs, IPO, NDA filing, commercial launch efforts and progress towards the Company's strategic objectives, our compensation committee exercised its discretion to award 90% of the remaining 25% of the bonus potential to each of our named executive officers.

The table below sets forth the amounts awarded by our compensation committee in January 2011 to our named executive officer in connection with their 2010 annual incentive compensation for satisfaction of the Company's 2010 corporate goals, satisfaction of the named executive officers individual goals, and the 2010 discretionary or subjective bonus.

Name	Target	Actual Bonus
C. Daniel Myers	\$ 147,098	\$ 119,149
Richard S. Eiswirth	\$ 68,640	\$ 60,746
Kenneth Green, Ph.D.	\$ 67,600	\$ 56,615
Susan Caballa	\$ 59,488	\$ 48,631
David Holland	\$ 61,152	\$ 55,037

See the columns titled "Bonus" and "Non-Equity Incentive Compensation" in the 2010 Summary Compensation Table for additional information related to the performance bonuses earned by our named executive officers.

Long-Term Incentive Compensation. We utilize equity awards for our long-term equity compensation to ensure that our executive officers have a continuing stake in our long-term success. To date, our long-term incentive awards have primarily been in the form of options to purchase our common stock. Because our executive officers are awarded stock options with an exercise price equal to the fair market value of our common stock on the date of grant, these options will have value to our executive officers only if the market price of our common stock increases after the date of grant. Typically, our stock option grants to new executives vest at the rate of 25% after the first year of service, with the remainder vesting ratably over the subsequent 36 months and our stock option grants to continuing executives vest in equally monthly installments over a four year period. We do not currently use a targeted cash/equity split to set officer compensation.

Prior to our IPO, our board of directors historically determined the value of our common stock based upon the consideration of several factors impacting our valuation. We do not have any program, plan or obligation that requires us to grant equity compensation on specified dates. Since becoming a public company, we have and intend to continue to grant equity awards at fair market value (the closing price of our common stock on the Nasdaq Global Market) on the date that the grant occurs. We anticipate granting equity awards to our executive officers on an annual basis.

Generally, in order to align his or her interests with those of our stockholders, a significant stock option grant is made to an executive officer at the first regularly scheduled meeting of the compensation committee after the officer commences employment. Generally, the compensation committee determined the size of the grant based in part on its review of peer group and other publicly available data.

In November 2010, the compensation committee granted our named executive officers options to purchase shares of the Company's common stock under the Company's 2010 Equity Incentive Plan at an exercise price equal to \$11.15 per share, the closing price per share of the Company's common stock on the Nasdaq Global Market on the date of grant.

The options vest in equally monthly installments over a period of four years from the date of grant. As discussed above, the number of options granted to our named executive officers was determined with the goal of setting each executive officer's total annual compensation at a level at or near the median of the comparable positions with the updated peer group identified by the compensation committee with the assistance of Hewitt Associates in the fourth quarter of 2010.

Table of Contents

The following table sets forth the numbers of shares underlying the option grants made to the named executive officers.

	Number of Shares Underlying Option Grant
C. Daniel Myers	97,185
Richard S. Eiswirth	68,153
Kenneth Green, Ph.D.	54,057
Susan Caballa	39,391
David Holland	43,864
Total	302,650

The compensation committee plans to consider future equity awards for executive officers annually based upon recommendations from our Chief Executive Officer and in comparison to their current peer group. We believe that the resulting overlapping vesting schedule from awards made in prior years, together with the number of shares subject to each award, helps ensure a meaningful incentive to remain in our employ and to enhance stockholder value over time.

Severance and Change in Control

Each of our named executive officers has a provision in his or her employment agreement providing for certain severance benefits in the event of termination without cause, or the executive's decision to terminate his or her employment for good reason after a change in control. These severance provisions are described in the Employment Agreements section below.

In June 2008 our board of directors established acceleration provisions for unvested options in the event of a change in control. Under these provisions, in the event of change of control, each executive will receive 12 months of additional vesting for any stock options that are outstanding and unvested as of the date of such transaction. In addition, unvested options vest in full in the event that the stock options are not continued or replaced with an alternate security, the executive is terminated without cause, or the executive terminates his or her employment for good reason within 12 months of a change of control. See Employment Agreements with our Executive Officers and Estimated Benefits and Payments Upon Termination of Employment below for estimates of severance and change in control benefits.

We believe these severance and change in control arrangements mitigate some of the risk that exists for executives working in a smaller company. These arrangements are intended to attract and retain qualified executives who could have other job alternatives that may appear to them to be less risky absent these arrangements. Because of the significant acquisition activity in the life science industry, there is a possibility that we could be acquired in the future. Accordingly, we believe that the larger severance packages resulting from terminations related to change in control transactions, and bonus and vesting packages relating to the change in control itself, will provide an incentive for these executives to help execute such a transaction from its early stages until closing.

No material changes were made to these benefits in 2010.

Other Benefits

Our executive officers are eligible to participate in all of our employee benefit plans, such as medical, dental, vision, group life, disability and accidental death and dismemberment insurance and our 401(k) plan, in each case on the

same basis as other employees, subject to applicable law. We also provide vacation and other paid holidays to all employees, including our executive officers, which are comparable to those provided at peer companies. At this time, we do not provide special benefits or other perquisites to our executive officers.

Table of Contents***Recent Developments***

In the fourth quarter of 2010, based on the compensation committees revised compensation philosophy discussed above under the heading Peer Group, following review of the executive compensation data of an updated group of peer companies, the compensation committee increased the 2011 base salary for our named executive officers as set forth below and increased the target bonus for our chief executive officer to 55% of his annualized base salary, and 40% of annualized base salary for each of the other named executives.

	2011 Base Salary	% Increase from 2010 Base Salary
C. Daniel Myers	\$ 431,650	17.4%
Richard S. Eiswirth	\$ 311,383	4.1%
Kenneth Green, Ph.D.	\$ 294,228	8.8%
Susan Caballa	\$ 253,499	6.5%
David Holland	\$ 285,634	4.6%

Policies Regarding Recovery of Awards

Our compensation committee has not adopted a policy on whether or not we will make retroactive adjustments to any cash or equity-based incentive compensation paid to executive officers (or others) where the payment was predicated upon the achievement of financial results that were subsequently the subject of a restatement. However, we expect to implement a clawback policy in fiscal 2011 in accordance with the requirements of the Dodd-Frank Act and the regulations that will issue under that act. We elected to wait until the SEC issues guidance about the proper form of a clawback policy in order to ensure that we implement a fully compliant policy at one time, rather than implementing a policy this year that may require amendment next year after the SEC regulations are released.

Tax and Accounting Treatment of Compensation

Section 162(m) of the Internal Revenue Code places a limit of \$1.0 million per person on the amount of compensation that we may deduct in any one year with respect to each of our named executive officers other than the Chief Financial Officer. There is an exemption from the \$1.0 million limitation for performance-based compensation that meets certain requirements. All grants of options under our 2010 Equity Incentive Plan are intended to qualify for the exemption. Grants of restricted shares or stock units under our 2010 Equity Incentive Plan may qualify for the exemption if vesting is contingent on the attainment of objectives based on the performance criteria set forth in the plan and if certain other requirements are satisfied. Grants of restricted shares or stock units that vest solely on the basis of service cannot qualify for the exemption. Our current cash incentive plan is not designed to qualify for the exemption. To maintain flexibility in compensating executive officers in a manner designed to promote varying corporate goals, our compensation committee has not adopted a policy requiring all compensation to be deductible. Although tax deductions for some amounts that we pay to our named executive officers as compensation may be limited by section 162(m), that limitation does not result in the current payment of increased federal income taxes by us due to our significant net operating loss carry-forwards. Our compensation committee may approve compensation or changes to plans, programs or awards that may cause the compensation or awards to exceed the limitation under section 162(m) if it determines that such action is appropriate and in our best interests.

We account for equity compensation paid to our employees under the rules of FASB ASC Topic 718, which requires us to estimate and record an expense for each award of equity compensation over the service period of the award.

Accounting rules also require us to record cash compensation as an expense at the time the obligation is accrued. We have not tailored our executive compensation program to achieve particular accounting results.

Table of Contents

Trading Plans

We have authorized our executive officers to enter into trading plans established according to Section 10b5-1 of the Exchange Act with an independent broker-dealer (broker) designated by us. These plans may include specific instructions for the broker to exercise vested options and sell Company stock on behalf of the executive officer at certain dates, if our stock price is above a specified level or both. The executive officer no longer has control over the decision to exercise and sell the securities in the plan, unless he or she amends or terminates the trading plan during a trading window. Plan modifications are not effective until the 91st day after adoption. The purpose of such plans is to enable executive officers to recognize the value of their compensation and diversify their holdings of our stock during periods in which the executive officer would be unable to sell our common stock because material information about us had not been publicly released. As of the record date, two of our executive officers had a trading plan in effect.

Report of the Compensation Committee⁴

We, as members of the compensation committee of the board of directors, have reviewed and discussed the Compensation Discussion and Analysis contained in this proxy statement with management. Based on such review and discussion, we have recommended to the board of directors that the Compensation Discussion and Analysis be included in this proxy statement and incorporated by reference into our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

SUBMITTED BY THE COMPENSATION
COMMITTEE OF THE BOARD OF DIRECTORS⁵

Brian K. Halak, Ph.d. (Chairman)
Mark J. Brooks
Bryce Youngren⁶

⁴ The material in this report shall not be deemed to be (i) soliciting material, (ii) filed with the SEC, (iii) subject to Regulations 14A or 14C of the Exchange Act, and/or (iv) subject to the liabilities of Section 18 of the Exchange Act. This report shall not be deemed incorporated by reference into any of our other filings under the Exchange Act or the Securities Act of 1933, as amended, except to the extent the Company specifically incorporates it by reference into such filing.

⁵ Hove resigned as a member of the compensation committee effective as of April 18, 2011 and therefore did not sign this report.

⁶ Appointed as a member of the compensation committee effective as of April 18, 2011.

Table of Contents**2010 Summary Compensation Table**

The following table summarizes the compensation that we paid to our Chief Executive Officer, Chief Financial Officer and each of our three other most highly compensated executive officers during the year ended December 31, 2010. We refer to these executive officers in this proxy statement as our named executive officers.

Name and Principal Position	Year	Salary (\$)	Bonus \$(1)	Option Awards \$(2)	Non-Equity Incentive Plan Compensation	All Other Compensation	Total (\$)
					\$(3)	\$(4)	
C. Daniel Myers Chief Executive Officer	2010	\$ 367,744	\$ 33,097(5)	\$ 833,216	\$ 86,052(5)	\$ 1,764	\$ 1,321,873(7)
	2009	353,600	35,360	365,380	108,909	1,721	864,970
Richard S. Eiswirth Chief Operating Officer and Chief Financial Officer	2010	274,560	15,444(5)	584,310	45,302(5)	6,264	925,880(7)
	2009	249,600	15,600(6)	97,690	48,048(6)	6,221	417,159
Kenneth Green, Ph.D. Senior Vice President, Scientific Affairs and Chief Scientific Officer	2010	270,400	15,210(5)	463,458	41,405(5)	6,264	796,737(7)
	2009	260,000	16,250(6)	126,652	50,050(6)	6,221	459,173
Susan Caballa Senior Vice President, Regulatory and Medical Affairs	2010	237,952	13,385(5)	337,719	35,247(5)	6,246	630,549(7)
	2009	228,800	14,300	83,995	43,186	6,174	376,455
David Holland Senior Vice President, Sales and Marketing	2010	244,608	13,759(5)	376,068	41,278(5)	6,218	681,931(7)
	2009	218,400	13,650(6)	94,513	42,042(6)	6,128	374,733

- (1) The amounts set forth in this column represent the subjective portion of our annual bonus awards paid to the named executive officers based on the board of directors' approval. See Compensation Discussion and Analysis above for further discussion of this discretionary bonus.
- (2) The amounts reported in this column represent the aggregate grant date fair value of option awards computed in accordance with FASB ASC Topic 718. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. See Note 12 of the Notes to the Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2010 for a discussion of our assumptions in determining the ASC 718 values of our option awards.
- (3) The Non-Equity Incentive Plan Compensation represents the bonus paid to executives based on personal and corporate targets as defined in our Incentive Compensation Bonus Plan and approved by the board of directors.
- (4) All Other Compensation represents 401(k) matching contributions and short-term and long-term disability gross-ups paid on an executive's behalf.
- (5) Represents amount paid in January 2011, but earned for fiscal year 2010.

(6) Represents amount paid in January 2010, but earned for fiscal year 2009.

(7) In 2010, salary, bonus and non-equity incentive plan compensation accounted for the following percentages of the total compensation of our named executive officers:

Name	Salary	Bonus	Non-Equity Incentive Plan Compensation
C. Daniel Myers	28%	3%	7%
Richard S. Eiswirth	30%	2%	5%
Kenneth Green, Ph.D.	34%	2%	5%
Susan Caballa	38%	2%	6%
David Holland	36%	2%	6%

Table of Contents**Grants of Plan-Based Awards in 2010**

The following table sets forth each plan-based award granted to our named executive officers during the year ended December 31, 2010.

Name	Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1)				Equity Incentive Plan Awards All Other Option Awards:		
	Threshold (\$)	Target (\$)	Maximum (\$)	Grant Date	Number of Securities Underlying Options (#)(2)	Exercise of Base Price of Option Awards (\$/Sh)	Grant Date Fair Value of Option Awards \$(3)
C. Daniel Myers	(4)	\$ 110,323	(5)	11/3/2010	97,185	\$ 11.15	\$ 833,216
Richard S. Eiswirth	(4)	51,480	(5)	11/3/2010	68,153	11.15	584,310
Kenneth Green, Ph.D.	(4)	50,700	(5)	11/3/2010	54,057	11.15	463,458
Susan Caballa	(4)	44,616	(5)	11/3/2010	39,391	11.15	337,719
David Holland	(4)	45,864	(5)	11/3/2010	43,864	11.15	376,068

(1) Represents bonus payable to executives based on personal and corporate targets as defined in our Incentive Compensation Bonus Plan and approved by the board of directors.

(2) Each option vests in equal monthly installments over a four year period of continuous service.

(3) The amounts reported in this column represent the aggregate grant date fair value of option awards computed in accordance with FASB ASC Topic 718. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. A more detailed discussion of the assumptions used in the valuation of option awards made in fiscal year 2010 may be found in Note 12 of the Notes to the Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2010.

(4) No threshold amount is included because the Incentive Bonus Compensation Plan does not provide for a minimum non-zero payout amount.

(5) No maximum amount is included because the Incentive Bonus Compensation Plan does not provide for maximum payout amounts in the event of over achievement of both corporate and individual goals.

Outstanding Equity Awards as of December 31, 2010

The following table sets forth information regarding each option held by each of our named executive officers as of December 31, 2010. The vesting applicable to each outstanding option is described in the footnotes to the table below.

For a description of the acceleration of vesting provisions applicable to the options held by our named executive officers, please see the section titled "Estimated Benefits and Payments Upon Termination of Employment" below.

Name	Initial Vesting Date(1)	Option Awards		Option Exercise Price (\$)	Option Expiration Date
		Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable		
C. Daniel Myers	7/7/2005	22,775		\$ 2.04	7/7/2014
	11/22/2006	55,147		1.33	1/1/2016
	11/22/2006	55,147		1.33	10/12/2016
	12/13/2008	133,413	44,470	1.40	12/13/2017
	3/20/2009	110,073	50,034	2.42	3/20/2018
	8/25/2010	8,220	18,086	4.02	8/25/2019
	12/22/2010	19,963	59,888	4.02	8/25/2019
	12/3/2010(2)	2,024	95,161	11.15	11/3/2020

Table of Contents

Name	Initial Vesting Date(1)	Option Awards		Option Exercise Price (\$)	Option Expiration Date	
		Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable			
Richard S. Eiswirth	10/31/2006	13,625		2.04	10/31/2015	
	10/31/2006	96,669		1.33	1/1/2016	
	11/22/2007	51,471		1.33	10/12/2016	
	12/13/2008	24,820	8,274	1.40	12/13/2017	
	3/20/2009	31,863	14,484	2.42	3/20/2018	
	6/25/2009	18,382	11,029	3.88	6/25/2018	
	8/25/2010	2,197	4,836	4.02	8/25/2019	
	12/22/2010	5,338	16,012	4.02	8/25/2019	
	12/3/2010(2)	1,419	66,734	11.15	11/3/2020	
	Kenneth Green, Ph.D.	8/2/2005	73,529		2.04	8/2/2014
1/3/2006		14,706		2.04	1/1/2015	
11/22/2006		44,118		1.33	1/1/2016	
11/22/2006		44,118		1.33	10/12/2016	
11/22/2007		22,059		1.33	10/12/2016	
3/1/2008		55,147	3,677	1.40	3/1/2017	
12/13/2008		19,558	6,519	1.40	12/13/2017	
3/20/2009		46,347	21,067	2.42	3/20/2018	
8/25/2010		2,849	6,269	4.02	8/25/2019	
12/22/2010		6,919	20,759	4.02	8/25/2019	
12/3/2010(2)		1,126	52,931	11.15	11/3/2020	
Susan Caballa		7/7/2005	8,931		2.04	7/4/2014
		2/18/2006	20,480		2.04	2/18/2015
	11/22/2006	44,118		1.33	1/1/2016	
	11/22/2006	44,118		1.33	10/12/2016	
	3/1/2008	13,786	920	1.40	3/1/2017	
	12/13/2008	2,761	921	1.40	12/13/2017	
	3/20/2009	31,863	14,484	2.42	3/20/2018	
	8/25/2010	1,899	4,179	4.02	8/25/2019	
	12/22/2010	4,612	13,837	4.02	8/25/2019	
	12/3/2010(2)	820	38,571	11.15	11/3/2020	
	David Holland	7/7/2005	26,795		2.04	7/7/2014
		11/22/2006	33,088		1.33	1/1/2016
		11/22/2006	33,088		1.33	10/12/2016
12/13/2008		1,465	489	1.40	12/13/2017	
3/20/2009		34,760	15,800	2.42	3/20/2018	
8/25/2010		2,137	4,702	4.02	8/25/2019	
12/22/2010		5,189	15,570	4.02	8/25/2019	
12/3/2010(2)		913	42,951	11.15	11/3/2020	

- (1) Unless otherwise set forth below, 25% of each option vests upon continuous service through the Initial Vesting Date shown in the table. Thereafter, the option vests in 12 equal quarterly installments over the next three years of service.
- (2) Vests in 48 equal monthly installments over a four year period beginning on the Initial Vesting Date.

Option Exercises and Stock Vested During 2010

There were no option exercises by our named executive officers in 2010. There were no share vesting events for awards held by our named executive officers in 2010.

Table of Contents**Employment Agreements with Our Executive Officers**

We have entered into employment agreements with each of our named executive officers. The employment agreements provide for a starting base salary and a potential annual bonus, which is subject to adjustment by our board of directors from time to time. In addition, each of the agreements provide that if we terminate the named executive officer's employment without cause or if he or she resigns for good reason, the named executive officer is entitled to one year of his or her base salary at the rate in effect at the time of his termination paid in 12 equal monthly installments. The named executive officer will also be entitled to the portion of his or her bonus earned up until termination. In addition, the named executive officer is entitled to reimbursement of his or her premiums for medical insurance coverage under COBRA for 12 months after the date of termination or until the named executive officer is eligible to be covered under a medical insurance plan by a subsequent employer. The employment agreements also provide for acceleration of any unvested options held by our named executive officers in the event of a change of control. Under these provisions, in the event of change of control, each executive will receive 12 months of additional vesting for any stock options that are outstanding and unvested as of the date of such transaction. In addition, unvested options vest in full in the event that the stock options are not continued or replaced with an alternate security, the executive is terminated without cause, or the executive terminates his or her employment for good reason within 12 months of a change of control.

The following table sets forth the base salary and potential bonus of each of our named executive officers under their respective employment agreements at January 1, 2010 and 2011, respectively.

Name	Base Salary	Potential Bonus
C. Daniel Myers	\$367,744 (increased to \$431,650 effective January 2011)	\$147,098 (increased to \$237,408 effective January 2011)
Richard S. Eiswirth	\$259,584(1) (increased to \$311,383 effective January 2011)	\$64,896(1) (increased to \$124,553 effective January 2011)
Kenneth Green, Ph.D.	\$270,400 (increased to \$294,228 effective January 2011)	\$67,600 (increased to \$117,691 effective January 2011)
Susan Caballa	\$237,952 (increased to \$253,499 effective January 2011)	\$59,488 (increased to \$101,400 effective January 2011)
David Holland	\$227,136(2) (increased to \$285,634 effective January 2011)	\$56,784(2) (increased to \$114,254 effective January 2011)

(1) Effective August 11, 2010, Mr. Eiswirth's 2010 base salary was increased to \$299,000 and his 2010 potential bonus was increased to \$74,750.

(2) Effective August 11, 2010, Mr. Holland's 2010 base salary was increased to \$273,000 and his 2010 potential bonus was increased to \$68,250.

For purposes of severance payments, "good reason" is defined in all amended and restated employment agreements as an executive resigning within 12 months after one of the following conditions has come into existence without the executive's consent:

a reduction of the executive's base salary;

a material adverse change in the executive's primary responsibilities or duties;

a geographical relocation of our corporate headquarters, or the executive's primary business location, to a location that is more than 35 miles from the present location; or

any material breach by us of the employment agreement.

The executive must provide us with written notice within 90 days after a good reason condition comes into the existence, and we have 30 days to remedy the condition after receipt of the notice. For purposes of option acceleration, good reason is defined in all applicable employment agreements as:

a material adverse change in the executive's responsibilities or duties;

a geographical relocation of our corporate headquarters, or the executive's primary business location, to a location that is more than 35 miles from the present location; or

any breach by us of the employment agreement that is material and not cured, or capable of being cured, within 30 days after the executive gives us and our board of directors written notice.

Table of Contents**Estimated Benefits and Payments Upon Termination of Employment**

The following table describes the potential payments and benefits upon termination of our named executive officers employment before or after a change in control of our Company as described above, as if each officer's employment terminated as of December 31, 2010, the last business day of the 2010 fiscal year.

Name	Benefit	Voluntary Resignation or Termination for Cause	Termination without Cause or for Good Reason Prior to Change in Control	Termination without Cause or for Good Reason after Change in Control
C. Daniel Myers				
	Salary	\$ 0	\$ 367,744	\$ 367,744
	Bonus	0	147,098(1)	147,098(1)
	Benefit Continuation	0	12,683	12,683
	Accrued Vacation(2)	2,829	2,829	2,829
	Accelerated Vesting			1,293,526(3)
	<i>Total value</i>	\$ 2,829	\$ 530,354	\$ 1,823,880
Richard S. Eiswirth				
	Salary	\$ 0	\$ 299,000	\$ 299,000
	Bonus	0	74,750(1)	74,750(1)
	Benefit Continuation	0	20,143	20,143
	Accrued Vacation(2)	3,450	3,450	3,450
	Accelerated Vesting			393,875(3)
	<i>Total value</i>	\$ 3,450	\$ 397,343	\$ 791,218
Kenneth Green, Ph.D.				
	Salary	\$ 0	\$ 270,400	\$ 270,400
	Bonus	0	67,600(2)	67,600(1)
	Benefit Continuation	0	20,143	20,143
	Accrued Vacation(2)	12,480	12,480	12,480
	Accelerated Vesting			490,107(3)
	<i>Total value</i>	\$ 12,480	\$ 370,623	\$ 860,730
Susan Caballa				
	Salary	\$ 0	\$ 237,952	\$ 237,952
	Bonus	0	59,488(1)	59,488(1)
	Benefit Continuation	0	13,279	13,279

Edgar Filing: ALIMERA SCIENCES INC - Form DEF 14A

	Accrued Vacation(2)	10,525	10,525	10,525
	Accelerated Vesting			88,003(3)
<i>Total value</i>		\$ 10,525	\$ 321,244	\$ 409,247
David Holland				
	Salary	\$ 0	\$ 273,000	\$ 273,000
	Bonus	0	68,250(1)	68,250(1)
	Benefit Continuation	0	20,143	20,143
	Accrued Vacation(2)	1,050	1,050	1,050
	Accelerated Vesting			259,089(3)
<i>Total value</i>		\$ 1,050	\$ 362,443	\$ 621,532

Table of Contents

- (1) Represents target bonus for 2010. Bonus payments in the year of termination would be based on the actual earned bonus and may be less than the target bonus.
- (2) Based on each executive officer's base salary in effect at the end of 2010 and the number of accrued but unused vacation days at the end of 2010.
- (3) The value of option acceleration was calculated based on the assumption that the officer's employment was terminated and the change in control (if applicable) occurred on December 31. The value of the vesting acceleration was calculated by multiplying the number of unvested shares subject to each option by the difference between the \$10.38 closing market price of shares of the Company's common stock on December 31, 2010 (the last trading day in fiscal 2010) and the exercise price of the option.

Table of Contents

PROPOSAL NO. 3

ADVISORY NON-BINDING VOTE ON EXECUTIVE COMPENSATION

Our board of directors recognizes the interests our investors have in the compensation of our executives. In recognition of that interest and as required by the recently enacted Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or the Dodd-Frank Act, we are providing our stockholders with the opportunity to vote to approve, on an advisory (nonbinding) basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with the SEC's rules.

As described in detail in our Compensation Discussion and Analysis, our executive compensation programs are designed to attract, motivate and retain our named executive officers, who are critical to our success and will drive the creation of stockholder value. Under these programs, our named executive officers are rewarded for the achievement of specific annual, long-term and strategic goals, corporate goals and the realization of increased stockholder value. Please read the Compensation Discussion and Analysis for additional details about our executive compensation programs, including information about the fiscal year 2010 compensation of our named executive officers.

The compensation committee of our board of directors continually reviews the compensation programs for our named executive officers to ensure they achieve the desired goals of aligning our executive compensation structure with our stockholders' interests and current market practices. As described in detail in our Compensation Discussion and Analysis our compensation programs are designed to motivate our executives to create a successful company. We believe that our compensation program, with its balance of short-term incentives (including cash bonus awards) and long-term incentives (including equity awards that vest over up to four years) reward sustained performance that is aligned with long-term stockholder interests.

We are asking our stockholders to indicate their support for our named executive officer compensation as described in this proxy statement. This proposal, commonly known as a "say-on-pay" proposal, gives our stockholders the opportunity to express their views on our named executive officers' compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement. Stockholders are encouraged to read the Compensation Discussion and Analysis, the accompanying compensation tables, and the narrative disclosure. Accordingly, we will ask our stockholders to vote **FOR** the following resolution at the Annual Meeting:

RESOLVED, that the compensation paid to the Company's named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED.

In order for Proposal 3 to be approved, holders of a majority of all those outstanding shares present in person, or represented by proxy, and cast either affirmatively or negatively at the Annual Meeting must vote **FOR** Proposal 3. Abstentions and broker non-votes will not be counted either **FOR** or **AGAINST** the proposal and will have no effect on the proposal. Because Proposal 3 is a non-routine matter, broker non-votes are expected to exist in connection with this matter.

As an advisory vote, the result will not be binding on our board of directors or compensation committee. Our board of directors and our compensation committee value the opinions of our stockholders and expect to take into account the outcome of the vote when considering future executive compensation decisions to the extent they can determine the cause or causes of any significant negative voting results.

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE APPROVAL OF THE
COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS**

Table of Contents

PROPOSAL NO. 4

**ADVISORY NON-BINDING VOTE ON THE FREQUENCY OF A VOTE ON
EXECUTIVE COMPENSATION**

The Dodd-Frank Act also enables our stockholders to indicate how frequently we should seek an advisory vote on the compensation of our named executive officers, as disclosed pursuant to the SEC's compensation disclosure rules, such as Proposal 3 of this proxy statement. By voting on this Proposal 4, stockholders may indicate whether they would prefer an advisory non-binding vote on named executive officer compensation once every 1, 2, or 3 years. The Dodd-Frank Act requires the Company to hold this advisory vote on the frequency of the say-on-pay vote at least once every six years.

After careful consideration of this Proposal, our board of directors has determined that an advisory non-binding vote on executive compensation that occurs every 1 year is the most appropriate alternative for our Company, and therefore our board of directors recommends that you vote for a 1-year interval for the advisory vote on executive compensation.

In formulating its recommendation, our board of directors considered that an annual advisory non-binding vote on executive compensation will allow our stockholders to provide us with their direct input on our compensation philosophy, policies and practices as disclosed in the proxy statement every year. Additionally, an annual advisory vote on executive compensation is consistent with our policy of seeking input from, and engaging in discussions with, our stockholders on corporate governance matters and our executive compensation philosophy, policies and practices. We understand that our stockholders may have different views as to what is the best approach for our Company and we look forward to hearing from our stockholders on this Proposal.

Stockholders who have concerns about executive compensation during the interval between say-on-pay votes are welcome to bring their specific concerns to the attention of our board of directors. Please refer to Corporate Governance Communications to the Board of Directors in the proxy statement for information about communicating with our board of directors.

You may cast your vote on your preferred voting frequency by choosing the option of 1 year, 2 years, 3 years or abstain from voting when you vote in response to the resolution set forth below. Therefore, stockholders will not be voting to approve or disapprove the recommendation of our board of directors. The choice among the four choices included in the resolution which receives the highest number of votes will be deemed the choice of the stockholders. Our board of directors and the compensation committee will take into account the outcome of the vote when considering the frequency of future advisory votes on executive compensation. However, because this vote is advisory and not binding on the board of directors or our Company in any way, the board of directors may decide that it is in the best interests of our stockholders and our Company to hold an advisory vote on executive compensation more or less frequently than the option chosen by the stockholders.

RESOLVED, that the option of once every 1 year, 2 years, or 3 years that receives the highest number of votes cast for this resolution will be determined to be the preferred frequency with which the Company is to hold a stockholder vote to approve the compensation of the named executive officers, as disclosed pursuant to the Securities and Exchange Commission's compensation disclosure rules (which disclosure shall include the Compensation Discussion and Analysis, the Summary Compensation Table, and the other related tables and disclosure).

**OUR BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE OPTION OF 1 YEAR
AS THE FREQUENCY WITH WHICH STOCKHOLDERS ARE PROVIDED A VOTE ON**

EXECUTIVE COMPENSATION

Table of Contents

NO INCORPORATION BY REFERENCE

In the Company's filings with the SEC, information is sometimes incorporated by reference. This means that we are referring you to information that has previously been filed with the SEC and the information should be considered as part of the particular filing. As provided under SEC regulations, the Audit Committee Report and the Compensation Committee Report contained in this proxy statement specifically are not incorporated by reference into any other filings with the SEC and shall not be deemed to be soliciting material. In addition, this proxy statement includes several website addresses. These website addresses are intended to provide inactive, textual references only. The information on these websites is not part of this proxy statement.

OTHER MATTERS

As of the time of preparation of this proxy statement, neither the board nor management intends to bring before the meeting any business other than the matters referred to in the Notice of Annual Meeting and this proxy statement. If any other business should properly come before the meeting, or any adjournment thereof, the persons named in the proxy will vote on such matters according to their best judgment.

Accompanying this proxy statement and posted on our website with this proxy statement, is our Annual Report on Form 10-K for the fiscal year ended December 31, 2010. Copies of our Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as filed with the SEC, is available free of charge on the investor relations portion of our website at www.alimerasciences.com.

CONTACT FOR QUESTIONS AND ASSISTANCE WITH VOTING

If you have any questions or require any assistance with voting your shares or need additional copies of this proxy statement or voting materials, please contact:

Investor Relations
Alimera Sciences, Inc.
6120 Winward Parkway,
Suite 290
Alpharetta, Georgia 30005

or

Call (310) 954-1105

It is important that your shares are represented at the Annual Meeting. Whether or not you plan to attend the Annual Meeting, please vote by using the Internet or by telephone or, if you received a paper copy of the proxy card by mail, by signing and returning the enclosed proxy card, so your shares will be represented at the Annual Meeting.

The form of proxy and this proxy statement have been approved by the board of directors and are being mailed or delivered to stockholders by its authority.

The Board of Directors of Alimera Sciences, Inc.

Alpharetta, Georgia

April 29, 2011

Table of Contents

**ALIMERA SCIENCES, INC.
6120 WINDWARD PARKWAY
SUITE 290
ALHARETTA, GA 30005**

VOTE BY INTERNET - www.proxyvote.com

Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.

ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS

If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years.

VOTE BY PHONE - 1-800-690-6903

Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you call and then follow the instructions.

VOTE BY MAIL

Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: p

KEEP THIS PORTION FOR YOUR RECORDS
DETACH AND RETURN THIS PORTION ONLY

THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.

The Board of Directors recommends you vote FOR the following:	For All	Withhold All	For All Except	To withhold authority to vote for any individual nominee(s), mark For All Except and write the number(s) of the nominee(s) on the line below.
	o	o	o	

1.

Election of Directors
Nominess

01 C. Daniel Myers
02 Calvin W. Roberts

The Board of Directors recommends you vote FOR proposals 2 and 3.

	For	Against	Abstain
2 TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2011.
3 TO HOLD AN ADVISORY NON-BINDING VOTE TO APPROVE THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.

The Board of Directors recommends you vote 1 YEAR on the following proposal:

	1 Year	2 Years	3 Years	Abstain
4 TO HOLD AN ADVISORY NON-BINDING VOTE ON THE FREQUENCY OF HOLDING A VOTE ON THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.

NOTE: In his discretion, the proxy holder is authorized to vote upon such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.

Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name, by authorized officer.

Signature [PLEASE SIGN WITHIN BOX]	Date	JOB #	Signature (Joint Owners)	Date	SHARES CUSIP # SEQUENCE #

Table of Contents

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Annual Report, Notice & Proxy Statement is/are available at www.proxyvote.com.

**ALIMERA SCIENCES, INC.
Annual Meeting of Stockholders
JUNE 8, 2011 9:30 AM
This Proxy is solicited on behalf of the Board of Directors**

for the Annual Meeting of Stockholders to be held on June 8, 2011

The undersigned appoints C. Daniel Myers and Richard S. Eiswirth, Jr., or any of them as shall be in attendance at the 2011 Annual Meeting of Stockholders, as proxy or proxies, with full power of substitution, to represent the undersigned at the Annual Meeting of Stockholders of Alimera Sciences, Inc. (the Company), to be held on June 8, 2011, at 9:30 a.m. local time, at the Atlanta Marriott Alpharetta, 5750 Windward Parkway, Alpharetta, Georgia 30005, and at any adjournments or postponements of the Annual Meeting, and to vote on behalf of the undersigned as specified in this Proxy all the Common Stock of the Company that the undersigned would be entitled to vote if personally present, upon the matters referred to on the reverse side hereof, and, in their sole discretion, upon any other business as may properly come before the Annual Meeting. The undersigned acknowledges receipt of the Notice of the Annual Meeting of Stockholders and of the accompanying proxy statement and revokes any proxy heretofore given with respect to such Annual Meeting. The votes entitled to be cast by the undersigned will be cast as instructed.

If this Proxy is executed, but no instruction is given, the votes entitled to be cast by the undersigned will be cast FOR each of the Board of Directors nominees for director in Proposal 1, FOR Proposal 2, FOR Proposal 3, and will be voted for 1 YEAR as the desired frequency in Proposal 4, each of which is set forth on the reverse side hereof.

The votes entitled to be cast by the undersigned will be cast in the discretion of the Proxy holders on any other matter that may properly come before the Annual Meeting and any adjournment or postponement thereof.

Continued and to be signed on reverse side